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Immune responses primed by endogenous heat shock proteins (HSPs), specifically gp96, have 
been used for immunotherapy of cancer. Immunization with low doses of gp96 primes a 
response that is dominated by T helper type 1 (Th1) cells and cytotoxic T lymphocytes (CTLs), 
which allows for recognition and killing of tumor cells. However, increasing the dose of gp96 
primes a response characterized by regulatory T (Treg) cells and immunosuppression. 
Although the T cell responses driving this dose dichotomy have been studied in multiple 
systems, innate mechanisms that control T cells in the context of gp96 immunization remains 
unknown. The antigen presenting cells (APCs) involved in this response are the main focus of 
Chapters 1 and 2 of this thesis. Here we show gp96 preferentially engages conventional and 
plasmacytoid dendritic cells (pDCs) under low and high doses respectively, through the HSP 
receptor CD91. We show that DNA methyltransferase 1 (DNMT1) is active in multiple APC 
population in response to gp96 stimulation, and that global DNA methylome and protein 
expression changes occur in these populations in response to in vivo immunization. 
Methylation-dependent upregulation of neuropilin-1 (Nrp1) on pDCs enables long term 
interactions with Treg cells that enhance their function in suppressing ongoing Th1 anti-tumor 
immunity. Our study defines a CD91-dependent mechanism through which gp96 controls 
dichotomous immune responses, relevant to the therapy of cancer and autoimmunity. 
Additionally, we are interested in the signaling pathways initiated by gp96-CD91 
interaction. Previous studies have shown that NF-κB and p38 MAPK are activated in HSP-
HEAT SHOCK PROTEIN GP96 DRIVES DICHOTOMOUS LYMPHOCYTE 
RESPONSES VIA DNA METHYLOME REMODELING AND STAT1 SIGNALING 
IN ANTIGEN PRESENTING CELLS 
 
Lauren B. Kinner-Bibeau, PhD 
University of Pittsburgh, 2017
 
 v 
responsive macrophages, but the consequences of p38 activation were not investigated. 
Chapter 3 will focus on the downstream mediators of p38, specifically the transcription factor 
STAT1, and the cytokine expression and secretion that follows. We show that gp96-treated 
macrophages upregulate STAT1-dependent cytokines as a result of STAT1 phosphorylation. 
This event requires intact CD91 and p38 MAPK. Importantly, STAT1 target CXCL10 is 
upregulated in response to gp96 and is critical for APC-NK cell crosstalk. Given that NK cells 
are required for anti-tumor immunity elicited by gp96 immunization, we hypothesize that 
STAT1 activation in responding APCs is necessary for tumor rejection.  
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1.0  PROJECT AIMS 
Immunogenic HSPs such as gp96 have been used for clinical treatment of cancer, however current 
vaccination strategies require improvement. Specifically, it is unknown why some patients do not 
respond to therapy using gp96. Though it is clear that gp96 drives dichotomous T cell responses 
following in vivo immunization, it is unknown what events must occur upstream in order to obtain 
fully activated Treg. A further understanding of how Treg can expand in response to higher doses 
of gp96 is required not only for improvement of gp96 as a cancer immunotherapy, but also for 
potential development of HD gp96 for treatment of autoimmune disease and solid organ 
transplantation. In this thesis, I aim to identify the APC subset responsible for driving Treg 
responses to gp96, the key mediators that are produced, and how expression of these mediators is 
regulated. Using fluorescent gp96 immunization, we have identified a subset of pDCs which 
increases uptake of gp96 at higher doses. Using whole genome methyl-sequencing, we have 
identified neuropilin-1 (Nrp1) as a key mediator in this response. Expression of Nrp1 by pDCs 
increases both in vivo and in vitro by qPCR and flow cytometry, and is required for pDC-Treg 
stabilization as measured by live cell imaging in the presence of Nrp1 neutralizing antibody. We 
have also confirmed that pDCs and Nrp1 are both required for in vivo HD gp96 responses, 
measured by cytotoxicity levels and Treg expansion. Finally, we have begun to understand STAT1 
signaling pathways that are activated in response to gp96 treatment. Together, these studies 
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improve our understanding of how APCs can respond to gp96 in different settings, and may 
provide insight to improve upon future immunotherapy. 
1.1 AIM 1: IDENTIFY APC SUBSETS THAT INTERACT WITH GP96 AT HIGHER 
DOSES IN VIVO 
We have established a model of HD gp96 immunization that results in establishment of tumor even 
when mice are immunized with irradiated tumor cells. Using CD91f/fCD11ccre mice, we will 
determine whether the gp96 receptor CD91 is required for HD gp96 immunity. We will also test 
whether Th1-skewing cytokine IL-12 can overcome suppressive immunity. Using fluorescently 
labeled gp96, we will also determine specifically which APC subsets in the draining lymph nodes 
interact with gp96 at different doses. CD91 expression in different APCs identified in this 
experiment will also be compared by flow cytometry. Finally, we will analyze the maturation 
profiles of various APC populations treated with gp96. The findings from this Aim reveal that 
CD91-expressing APCs are required for HD gp96 responses, and that pDCs may play a role in 
driving this response. 
1.2 AIM 2: DETERMINE EPIGENETIC AND TRANSCRIPTIONAL CHANGES IN 
APCS THAT CAN DRIVE SUPPRESSIVE TREG RESPONSES 
We will first test whether DNMTs, the enzymes responsible for the maintaining DNA methylation 
status in cells, are activated in APCs treated with gp96. To do this, APCs will be observed by 
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immunofluorescence and confocal microscopy for any changes in DNMT localization, and by 
western blot of nuclear proteins for any changes in DNMT expression. NF-κB inhibitor 
cardamonin will be included to test whether these events are NF-κB dependent. We will correlate 
these data with whole genome methyl-sequencing of gp96-responsive cells in LD and HD gp96 
immunized animals. Using the data generated by this study, we will then determine the role(s) of 
specific target genes that may contribute to suppressive immunity. One gene of interest that we 
have identified from this screen is Nrp1, which controls the interaction between Treg and APCs. 
Nrp1 expression on pDCs was confirmed in vitro and in LD and HD gp96 immunized animals. 
The ability of pDCs to interact with T cells (including Treg) will be verified by live cell 
microscopy, and Nrp1 dependence will be tested by addition of Nrp1 neutralizing antibody. Finally, 
the in vivo significance of both pDCs and Nrp1 will be tested using modified versions of our HD 
gp96 model, in which suppression is measured using an in vivo cytotoxicity assay and Treg 
expansion. This Aim demonstrates that although epigenetic modifications occur in gp96-
responsive APCs, there may be differences between individual subsets. Furthermore, it establishes 
a role for Nrp1+ pDCs in driving suppressive responses to gp96. 
1.3 AIM 3: EXAMINE STAT1 ACTIVATION IN GP96-TREATED MACROPHAGES 
Peritoneal macrophages will be treated with gp96 and phosphorylation of STAT1 at different sites 
will be observed by western blot. This will also be tested for dependence on p38 MAPK by 
pretreating macrophages with p38 inhibitor SB203580, and for CD91 dependence using CD91-
deficient macrophages. We will also test whether STAT1 phosphorylation requires soluble factors 
made in response to gp96 treatment by culturing CD91 deficient macrophages in supernatants from 
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treated wildtype cells. CXCL10 mRNA and protein levels will be examined by qPCR and 
Luminex. Binding of STAT1 to the CXCL10 promoter will be observed using chromatin 
immunoprecipitation. Finally, we will test whether CXCL10 is required for NK cell activation 
following co-culture with macrophages by incubated cells in the presence of blocking antibody 
against the receptor for CXCL10, CXCR3. This Aim demonstrates that CXCL10 is a main driver 
of APC-NK cell in response to gp96 stimulation. 
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2.0  INTRODUCTION 
HSPs are constitutively expressed intracellular chaperones present in all cell types, from 
prokaryotes to eukaryotes. Within host cells, HSPs can bind to endogenous peptides, lipids, and 
myriad other molecules. HSP-bound peptides can be of self, tumor, or pathogen origin, all of which 
can be synthesized by mammalian host cells under steady state, tumorigenesis, or infection, 
respectively. One of their main functions is to ensure the proper folding and assembly of proteins. 
Interestingly, certain members of the HSP family can elicit protective immunity when they interact 
with immune cells. These are broadly referred to as the immunogenic HSPs and are classified as 
danger-associated molecular patterns (DAMPs). Because of their unique antigen-binding and 
adjuvant properties, immunogenic HSPs have been used for cancer immunotherapy. Tumor-
derived HSP vaccines are promising, but treatment in human patients requires improvement. 
Whether lack of efficacy is due to some inherent property of HSPs or suppressive factors in the 
tumor microenvironment is not known. HSPs are able to suppress immune responses when given 
at higher doses or when they interact with suppressive APC subsets including pDCs and myeloid 
derived suppressor cells (MDSCs)(1, 2). Both of these suppressive APC subsets are highly 
prevalent in tumor-bearing hosts (3, 4). The suppressive response to HSPs is dominated by Treg 
which ultimately overcome the CTLs which are necessary for protective anti-tumor immunity (5, 
6). My thesis work has been to elucidate the mechanisms used by HSPs on a cellular, genomic, 
and immunologic level to better understand the dose dichotomy of HSP vaccination. Data 
generated by these studies may offer potential improvements upon current clinical trials and 
motivate interest in HSPs as a putative therapy for autoimmune disease. In this introduction, I will 
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review several key facets of HSPs, their receptor CD91, and prospective avenues by which HSPs 
may regulate immune responses. 
2.1 HSPS AND ANTI-TUMOR IMMUNITY 
2.1.1 Tumor antigens and generation of antigen-specific T cells 
Prior to the 1940’s, it was debated whether immunity was generated against tumors. Yet in 1943, 
it was demonstrated that mice immunized with tumor cells are immune to subsequent challenge 
with the same cells used for immunization (7). These and other studies revealed that tumors possess 
specific antigens which alert the immune system, resulting in killing of tumor cells. Tumor 
antigens may take the form of peptides or other molecules that are distinct from “normal” tissue 
due to the accumulation of genetic mutations or post-translational modifications. These antigens 
may be shared between tumors of the same histology, or truly unique to a specific tumor. Shared 
antigens tend to originate from molecules that are critical for tumor cell proliferation and survival, 
such as mutated B-RAF and MART-1 (8, 9). Unique tumor antigens are more difficult to identify, 
since in many cases they are specific to the patient from which the tumor was isolated (10). 
One goal of tumor immunotherapy is to immunize against tumor antigen mainly through 
generation of specific T cells (11). Briefly, antigen-specific CTLs require 3 signals in order to 
become activated: 1) antigen must be presented in the context of the major histocompatibility 
complex (MHC) on APCs, 2) co-stimulatory markers (i.e., CD40, CD80, CD86) on APCs must 
engage cognate receptors (i.e., CD28) on CTLs, and 3) activating cytokines such as IL-2 must be 
present to enhance CTL activation and survival. Successful immunization against tumors must 
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employ all three signals for full stimulation of CTLs. Additionally, elicitation of antigen-specific 
CTLs may require some degree of cognate CD4+ Th cell licensing of the APC via the CD40-CD40 
ligand (CD40L) axis and cytokines such as IFNγ (12, 13). 
2.1.2 HSPs as tumor rejection antigens 
Once it was discovered that tumors indeed elicit specific immunity, the question of how this 
immunity is generated was of key importance. There are several approaches to answer this 
question. Identification of tumor-specific antigens recognized by T cells is one such approach. 
However, the tools necessary for identifying such molecules were not readily available until 
recently. Another approach to this question involves biochemical/chromatographical fractionation 
of tumor cell homogenates to identify the immunogenic fraction. Using this method, Srivastava et 
al. immunized mice with different tumor cell fractions and challenged mice with live tumor cells 
to test for change in tumor growth (14). Fractions capable of eliciting protective immunity were 
then refractionated on additional chromatographical properties until homogenous fractions were 
obtained and identified. Through this work it was revealed that gp96 (and later, other immunogenic 
HSPs) was the protein responsible for tumor rejection. Specificity of the immune response elicited 
by gp96 was identical to irradiated tumor cells, in that gp96 preparations are protective only against 
the tumor cells from which they are derived (i.e., HSPs are not cross-protective). This is due to the 
tumor-specific peptides which are bound by gp96. 
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2.1.3 Association of antigenic peptides with immunogenic HSPs 
To date, six immunogenic HSPs have been characterized: gp96, hsp70, hsp90, calreticulin, hsp110, 
and grp170. Data presented in this section will focus on the first four HSPs listed since these are 
the most well studied. These immunogenic HSPs shuttle peptides from the proteasome to MHC 
during peptide processing in APCs. The peptides bound by HSPs thereby comprise the entire 
antigen repertoire of their host cell (15, 16). This is consistent with the absence of free peptides in 
cells due to the instability of free short peptides within the cytosol (16, 17). However, generation 
of endogenous peptides and presentation of these antigens on MHC I to T cells constantly occurs 
in cells. How then do these peptides circulate from the proteasome to MHC? Cytosolic hsp70 and 
hsp90 shuttle peptides from the proteasome to the transporter associated with antigen processing 
(TAP)(18-20). Once antigenic peptides pass through TAP, they are chaperoned by gp96 to the 
peptide loading complex (PLC)(16, 21). In the PLC, MHC is bound by calreticulin to retain it in 
its partially folded state (22, 23). Consistent with this, gp96 and calreticulin can be co-
immunoprecipitated with MHC (24). Work from our lab shows that treating cells with calreticulin-
specific siRNA results in accumulation of gp96-associated peptides and a reduction in MHC-
bound peptides, confirming that gp96 and calreticulin work together to relay peptides to MHC 
(16). Similarly, cells treated with hsp90 inhibitors generate “empty” MHC that is immediately 
internalized (20). Work using a TAP-deficient cell line (RMA/S) has shown that most, but not all, 
peptides that are bound to gp96 are required to first go through TAP (25).  
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2.1.4 Clinical trials using HSPs 
The immunostimulatory properties of HSPs thus provide an attractive therapy for cancer, since 
this circumvents the need for identification of specific tumor antigens and adjuvants. HSP 
vaccination has been shown to work both prophylactically and therapeutically in mouse models of 
cancer. Prophylactic treatment with tumor-derived HSPs usually involves isolation of tumor-
derived HSPs, injection of HSP, and challenge using the same tumor from which the HSP was 
derived. In mice, this has been done using numerous tumor models that vary across cell type and 
immunogenicity, including fibrosarcoma (14, 26, 27), B cell leukemia (28), colon carcinoma (29), 
and lung carcinoma (30). Therapeutic efficacy has also been demonstrated in animal models. This 
has been shown using two different approaches: 1) HSPs are derived from established tumors and 
injected into the tumor-bearing host, or 2) mice are injected with tumor-derived HSP 1-2 weeks 
following tumor challenge. Kovalchin et al. have shown that surgical removal of Meth A tumor 
and subsequent immunization with Meth A-derived gp96 provides a greater survival advantage 
over surgery alone (31). In the same study, it was shown that up to 31 days following tumor 
challenge, treatment with tumor-derived HSP resulted in decreased metastasis. Similar results have 
been shown using a B16 melanoma model (32). 
Similar to mouse models, human responses to HSP immunization have also been 
documented. In the case of humans, autologous HSPs are derived from the patient’s established 
tumor following resection of primary or metastatic tumor. Thus, in the setting of human cancer, 
HSPs are used as a therapeutic vaccine to resolve existing tumor and preclude malignancy. A 
summary of completed and ongoing clinical trials is provided below (Table 1; adapted from (33)). 
There have been no reports of severe side effects following HSP vaccination. As aforementioned, 
although the results from clinical trials using HSPs have been promising, some patients do not 
 10 
respond to HSP immunotherapy. This may be due to a variety of factors, including disease stage 
and the level of suppression within the tumor microenvironment. Clearly, a better understanding 
of how HSPs generate immunity is required to improve upon current treatments.  
Table 1: Summary of clinical trials using autologous HSP 
Tumor type Trial Year Outcome  Reference 
Varied I 2000 6/12 T cell, 8/12 NK cell expansion 
(FC, ELISPOT) 
(34) 
Colorectal II 2003 CD8+ T cell response (IFNγ 
ELISPOT); 79% OS, 33% DFS 
(35) 
Melanoma II 2002 2/28 CR, 3/28 SD, 11/28 CTL 
activation, 3/28 DFS 
(36) 
Melanoma II 2006 11/18 SD, 5/18 T cell, 12/18 NK cell 
response  
(37) 
Melanoma III 2008 No difference in OS (38) 
Melanoma I/II 2010 5/26 CTL response; 45% PFS (39) 
Non-Hodgkins lymphoma II 2003  (40) 
Non-Hodgkins lymphoma II 2007 8/20 SD (41) 
Pancreatic adeno-carcinoma I 2007 1/5 T cell response, 3/10 SD (42) 
Renal cell carcinoma II 2008 2/60 CR, 2/60 PR, 7/60 SD, 33/60 
progressed, 16/60 USD 
(43) 
Renal cell carcinoma III 2008 No difference in OS, recurrence in 
37.7% treated with gp96, 39.8% in 
untreated 
(44) 
Glioblastoma I/II 2012 11/12 T cell response (45) 
Glioblastoma II 2014 Ongoing (46) 
Glioblastoma II 2017 Ongoing  (47) 
Abbreviations: FC, flow cytometry; OS, overall survival; DFS, disease-free survival; CR, complete response; SD, 
stable disease; PFS, progression-free survival; PR, partial response; USD, unconfirmed stable disease 
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2.2 KNOWN MECHANISMS DRIVING HSP RESPONSES 
2.2.1 Cross-presentation of peptides chaperoned by HSPs 
Unlike presentation of endogenous peptides, cross-presentation is an activity that is restricted only 
to professional APCs, specifically dendritic cells (DCs). Extracellular antigen is taken up, 
processed, and presented on MHC I by APCs to CTLs. Naïve T cells can then be activated in 
response to foreign antigen, and this event called cross-priming. In general, cross-priming is 
measured by stimulating APCs with antigen or immunogenic cell lysates, co-culturing APCs with 
T cells, and measuring T cell activity by target cell lysis and/or cytokine production. Cross-priming 
activity can also be assayed in vivo by these methods and by detection of tetramer-positive CTLs. 
Substantial evidence exists for HSP-mediated cross-presentation and priming events (48-53). We 
have shown that depletion of major HSPs, but not antigenic proteins, from tumor cell lysates 
diminishes cross-priming (49). Similarly, using FITC-labeled ovalbumin (OVA) peptide, uptake 
and presentation by APCs was enhanced when OVA was bound to HSP (48). This study utilized 
HSPs bound to an extended 18-mer OVA peptide (EQLESIINFEKLLVLLKK) to demonstrate 
that the peptides require additional processing by the APC and do not merely associate with 
extracellular MHC. To show that gp96 can efficiently cross prime T cells, Staib et al. complexed 
gp96 to melanoma antigen MART-1 and co-incubated APCs primed with gp96/MART-1 with 
MART-1 specific CTL clone 2/9 (50). Interferon (IFN)γ production by CTLs was measured by 
ELISA. The authors found that pre-incubation of APCs with gp96/MART-1 complexes resulted 
in maximal IFNγ secretion by CTLs. Finally, antigen-specific CTLs can be detected in vivo 
following immunization with gp96. In one such study, gp96 was purified from a tumor cell line 
which expresses Escherichia coli (E. coli)-derived β-gal (51). Thus, if gp96 can cross-prime CTLs, 
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immunization with these gp96 preparations should result in β-gal specific T cells. Mice were 
injected with an intraperitoneal (i.p.) dose of gp96, and after 5 days their splenocytes were treated 
twice with β-gal peptide. Specific lysis of target cells by CTLs was significantly higher in gp96-
immunized mice compared with vehicle controls. The ability of HSPs to induce maturation in 
APCs will be discussed in the next section. Taken together, the ability of HSPs to bind antigenic 
peptides, induce cross-priming of T cells, and allow for efficient uptake explains how HSPs act as 
their own adjuvant to promote anti-tumor immunity.  
Importantly, HSP-bound peptides can also be presented on MHC II for activation of CD4+ 
T cells (52, 54, 55). Similar to CTL activity assays, CD4+ T cell activity against tumor cells can 
be measured in vitro by proliferation and IL-5 secretion. In one such study, CD4+ T cell clones 
(24D3 and 12D1) were obtained from mice immunized with Meth A tumor cells. Specific anti-
tumor activity was increased in 24D3 and 12D1 T cells when they were co-cultured with APCs 
pulsed with Meth A gp96 (52). Activated CD4+ T cells were also detected in vivo in gp96 
immunized hosts. Thus, HSP immunization can result in activation of both CD8+ and CD4+ T cells. 
2.2.2 CD91 as the receptor expressed on APCs 
APCs can take up extracellular matter via several pathways, including pinocytosis and receptor-
mediated endocytosis. By the mid-1990’s it was known that phagocytic cells were responsible for 
uptake and presentation of HSP-bound peptides, but the mechanism through which HSPs were 
being internalized was unknown. When compared with free peptide, HSP-bound peptides were re-
presented ~100-fold more efficiently (56). Given the efficient association of HSP-bound peptides 
with MHC (57), it was proposed that professional APCs express HSP-specific receptor(s) (58). To 
determine which, if any, receptor could bind HSP, membrane extracts derived from a detergent-
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treated macrophage-like cell line (RAW264.7) were applied to gp96-immobilized agarose columns 
(59). Through mass spectrometry, low density lipoprotein receptor related protein-1 (Lrp1; herein 
called CD91) was identified as the specific receptor for gp96. Following CD91-dependent 
internalization in macrophages, gp96 is trafficked to an endocytic compartment that is negative for 
transferrin, Rab5a, and CD1 (21). This compartment stained positive for Fc receptor and MHC I, 
which is consistent with gp96-associated peptide presentation on MHC. It was later confirmed that 
hsp70, hsp90, and calreticulin share CD91 as their receptor as well (60).  
In agreement with in vitro studies, our lab has demonstrated that gp96 binding in vivo is 
strictly dependent on CD91 expression by DCs (61). In this study, gp96 was fluorescently labeled 
and tracked following in vivo immunization. CD11b+CD11c+ conventional DCs (cDCs) were the 
main cell type associated with gp96. This population also expressed the highest level of CD91 
compared with other DC subsets observed in this study, suggesting that CD91 expression is 
correlated with HSP uptake. Following release from damaged cells in situ or through 
administration via vaccination, CD91 has been demonstrated to be essential for endocytosis of 
HSP-peptide complexes and cross-presentation of the chaperoned peptide (48, 52, 53, 59, 60, 62). 
Selective deletion of CD91 in cDCs renders mice incapable of priming Th1/CTL immune 
responses against tumors when immunized with gp96 (26). Therefore, in addition to binding 
antigenic peptides, HSPs provide an efficient means by which APCs can take up antigenic peptides 
via receptor-mediated endocytosis. 
Other endocytic receptors for HSPs have been proposed, including LOX-1 (63),  SRA (64), 
and SREC-1 (65). Toll-like receptor 2 (TLR2) and TLR4 have also been proposed to bind HSPs 
to activate various signaling pathways (66, 67), however binding to TLRs is not sufficient for 
internalization of HSP-peptide complexes as these receptors are not endocytic.   
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Presentation of peptide alone is not sufficient to generate anti-tumor immunity; co-
stimulatory molecules and cytokines are additionally required for full activation of T cells. In 
addition to its activity as an endocytic receptor, studies have shown that signaling pathways are 
activated downstream of HSP-CD91 interaction (62). This is not surprising since other CD91 
ligands can mediate proliferation, migration, maturation and differentiation in various cell types 
through this receptor using diverse signaling pathways (62, 68, 69). CD91 is expressed on multiple 
professional APCs, including macrophages, cDCs, and pDCs (Table 2). When gp96 binds to CD91 
on DCs, intracellular signaling pathways are activated to drive their phenotype (62, 70), as 
discussed in the next section. With the exception of pDCs, all APCs that have been tested increase 
maturation markers MHC II and CD86, but not CD80 or CD40. To our knowledge, there have 
been no reports comparing cytokine expression in response to gp96 using APCs with comparable 
levels of CD91. 
2.2.3 Signaling mediators activated by HSP-CD91 interaction 
The size, intricate secondary structure, and ligand repertoire of CD91 contribute to the complexity 
of signaling pathways initiated by this receptor. It is widely expressed on immune cells 
(particularly APCs), neurons, hepatocytes, adipocytes, and fibroblasts (60, 71-74). Due to its 
ability to bind a large array of ligands, many biological functions have been ascribed to CD91. It 
is indispensable for prenatal development, axonal regeneration, cholesterol metabolism, and 
uptake of apoptotic cells (68, 75-78). For the purpose of this thesis, its signaling activity and role 
in the immune response will be the main focus.  
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Table 2: CD91 expression in various APC subsets 
APC type HSP tested CD91 
expression  
Specific binding tested? Mediators/outcome  Ref 
RAW264.7 
mac, PECs 
gp96 MS Yes (in vitro); gp96-FITC 
uptake (IF, FC), blocked by 
α2M 
Re-presentation (MHC I) (59) 
BMDCs, PECs gp96, hsp90, 
hsp70, CRT 
IF Yes (in vitro); gp96-FITC 
uptake (FC), blocked by anti-
CD91 antibody 
Re-presentation (MHC I) (60) 
BMDCs, 
BMMs 
hsp70 
 
Yes (in vitro); blocked by 
anti-CD91 antibody 
Re-presentation (MHC 
II) 
(48) 
spleen DCs, 
BMDCs 
gp96 
 
Yes (in vitro); blocked by 
anti-CD91 antibody 
Re-presentation (MHC 
I,II) 
(52) 
RAW264.7 
mac, PECs 
gp96, hsp70, 
CRT 
WB, FC Yes (in vitro); blocked by 
anti-CD91 antibody 
p38 MAPK, NF-κB, 
TNF, IL-6, IL1β, 
maturation 
(62) 
CD11b+CD11c+ 
DCs 
gp96 WB, FC, IF Yes (in vivo); gp96A488 
uptake (IF, FC) 
Re-presentation (MHC I) (61) 
Adherent PECs gp96 FC 
 
CXCL10, RANTES, 
maturation 
(30) 
BMDCs, 
CD11c+ DCs 
gp96 WB, FC Yes (in vivo); blocked by 
CD91 inhibitor RAP 
IL-1β, maturation (26) 
pDCs,  
CD11b+CD11c+ 
DCs, BMDCs 
gp96 FC Yes (in vivo); gp96A488 
uptake (FC) 
Maturation (BMDCs), 
Nrp1 (pDCs), DNMT1 
(79) 
monocytes 
(human) 
hsp70 FC 
 
Maturation (80) 
pDCs (human) gp96 FC Yes (in vitro); gp96A488 
uptake, blocked by α2M 
IL-8, NF-κB (1) 
monocytic DCs 
(human) 
hsp70 WB, FC 
 
Re-presentation (MHC 
II), IL-5, IL-10, IFNγ 
(81) 
All APCs are murine derived unless otherwise stated. Abbreviations: BMDC, bone marrow-derived DC; BMM, 
bone marrow-derived macrophage; PEC, peritoneal exudate cells; mac, macrophage; CRT, calreticulin; MS, mass 
spectrometry; WB, western blot; FC, flow cytometry; IF, immunofluorescence; RAP, receptor-associated protein 
 
CD91 is a member of the low density lipoprotein (LDL) receptor family and is a type I 
transmembrane receptor. It is synthesized as a 600 kDa protein containing a furin cleavage site. 
Upon transport to the cell surface, CD91 is processed into two domains, the 515 kDa α-chain and 
the 85 kDa β-chain. The two domains are then non-covalently re-associated to form a functional 
receptor. The α-chain contains four potential ligand-binding domains, with most ligands binding  
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domains II and IV (68). The specific domain utilized by the various immunogenic HSPs is an area 
of active research. The β-chain is comprised of a short extracellular portion, a transmembrane 
domain, and an intracellular domain. This intracellular domain contains two NPXY motifs that 
become phosphorylated upon ligand binding and are responsible for binding pTyr-binding 
domains of signaling proteins (82). This event regulates association with adaptor molecules 
including Disabled-1 (DAB-1), FE65, JNK-interacting protein 1 (JIP1), postsynaptic density 
protein 95 (PSD-95), Src homology 2 domain containing protein (SHC), sorting nexin 17 (Snx17), 
and CED-6/GULP (83). Association of adaptor molecules seems to be ligand-specific, therefore 
HSP-CD91 binding may involve some but not all of the molecules listed above.  
 
Figure 1. HSP-CD91 interaction results in endocytosis and/or signaling. 
(1) HSP-CD91 interaction; (2) Endocytosis and processing; (3) Presentation of 
peptide and T cell activation; (4) Increased maturation markers and cytokines. 
 
 In addition to acting as an endocytic receptor, CD91 also acts as a signaling receptor in 
response to HSP binding (Figure 1). Previous studies from our lab have revealed that gp96 and 
calreticulin require the membrane distal but not proximal NPXY motif for NF-κB activation, 
CD4+ 
CD8+ 
p38 MAPK 
NFkB 
HSP 
CD91 
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whereas hsp70 utilizes both motifs (62). This suggests that different HSPs may employ different 
signaling pathways downstream of binding to CD91. Differential cytokine profiles in response to 
gp96, calreticulin, and hsp70 provide additional evidence for this idea (Table 3). All three HSPs 
can activate NF-κB and result in upregulation of co-stimulatory molecules including CD86 and 
MHC II. As a result, cDCs stimulated by extracellular gp96 undergo maturation. This satisfies all 
three criteria for generation of T cell immunity, making these DCs highly proficient at priming 
Th1/CTL responses.  
 
          Table 3. Cytokines produced by macrophages treated with immunogenic HSPs. 
 
gp96 calreticulin hsp70 Regulation 
IL-1ra ++++ ++ - NF-κB/STAT1 
G-CSF + + - MAPK 
IL-6 +++ +++ + NF-κB/MAPK 
CXCL10 + + + NF-κB/STAT1 
CCL17 + + + NF-κB 
IL-12p70 ++ ++ ++ NF-κB 
CXCL11 - + - NF-κB/STAT1 
TREM1 ++++ ++ - STAT1 
IL-1β +++ +++ +++ NF-κB 
TNF-α + ++++ - NF-κB 
Modified from Pawaria and Binder (62). 
 
Our lab has also shown that activation of p38 MAPK occurs for all HSPs tested (62). We 
have observed no evidence for activation of Akt, ERK1/2, JNK 1/2/3, MKK 3/6, or MAK2. p38 
MAPK is an ubiquitously expressed and evolutionarily conserved signaling molecule that is 
activated via phosphorylation. Immunological stress and cytokines activate the p38 pathway which 
contributes to expression of immune mediators (84-86). Along with PI3K, p38 is crucial for IL-12 
expression in DCs (87). Given this, it is not surprising that HSPs activate the p38 pathway in APCs 
since Th1 activation is a hallmark of gp96-mediated anti-tumor immunity. p38 MAPK can also 
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lead to activation of various transcription factors, including STAT1, ATF-2, MEF-2, CREB and 
Elk-1 (88).  
2.2.4 STAT1 as a potential mediator downstream of CD91 
Outside of its potential role as an intermediary of Th1 responses, it is currently unknown what the 
downstream consequences of p38 MAPK activation are for HSP-mediated immunity. MAPKs are 
activators of STAT1, a cytokine-activated transcription factor well known for its role in cellular 
responses to IFN stimulation. Expression of STAT1 target genes can lead to many outcomes 
including cell growth, antiviral activity, and inflammation (89). STAT1 phosphorylation in 
response to bacterial lipopolysaccharide (LPS) and cell stress is p38 MAPK-dependent (90). Our 
lab has previously shown that several STAT1-regulated cytokines are expressed in response to 
HSP stimulation in vitro (30, 62)(Table 3), suggesting that STAT1 may be activated in response 
to HSPs.  
Under basal conditions, STAT1 exists in an inactive state. It contains two potential 
phosphorylation sites, one tyrosine (Y701) and one serine (S727), both of which can trigger 
activation. Phosphorylation of Y701 induces SH2 domain-mediated dimerization and nuclear 
translocation of STAT1 in response to type I and II IFNs (91), whereas S727 phosphorylation 
increases transcription factor activity downstream of IFNγ (92). Upon phosphorylation, STAT1 
can form either a homodimeric or heterotrimeric complex. IFNγ induces formation of the 
STAT1/STAT1 homodimer which binds to palindromic gamma-activated sequences (GAS). 
Stimulation by type I IFN produces a STAT1/STAT2 heterodimer which subsequently forms a 
trimeric complex with IFN regulatory factor 9 (IRF9). The full trimeric complex has an affinity 
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for IFN-stimulated response elements (IRSE). Binding of STAT1 to GAS versus IRSE in part 
explains the specific gene signatures that arise in response to different IFNs.  
IFN-independent STAT1 activation is less well understood. Phosphorylation of STAT1 at 
S727 (pSTAT1-S727) is mediated by p38 MAPKs in response to cell stress in macrophages (90, 
93). Although phosphorylation at both Y701 and S727 is required for IFN-dependent nuclear 
translocation and gene expression, p38-mediated S727 phosphorylation alone is sufficient for 
activation of a distinct STAT1 signature in response to viral infection. pSTAT1-S727 induced by 
viral infection can upregulate cytokines IL-1β, IL-8, and ISG54 (93). Interestingly, rapid 
phosphorylation of S727, but not Y701, occurs in response to LPS, ultraviolet radiation, and IL-
1β (90, 94-96). Luu and colleagues have shown that stimulation of TLRs 2, 3, 4, 7, or 9 triggers 
S727 phosphorylation within 10-30 minutes, whereas only TLRs 3 and 4 can activate Y701 by 2 
hrs post stimulation (97). Rapid phosphorylation of S727 was directly associated with the TLR 
pathway via TRAF6. LPS-treated macrophages exhibited nuclear translocation of STAT1 and 
enhancement of NF-κB signaling upon S727 phosphorylation. Late phosphorylation of Y701 
seemingly occurs indirectly through autocrine signaling in response to factors produced in 
response to TLR stimulation. In all cases, activation of STAT1 was IFN-independent. We propose 
that immunogenic HSPs utilize a similar signaling pathway to upregulate STAT1 target cytokine 
expression. This hypothesis is tested in Chapter 3 of this thesis. 
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2.3 DOSE DICHOTOMY OF HSP-MEDIATED RESPONSES 
2.3.1 Application of HSP immunization in autoimmune disease and solid organ 
transplantation 
Vaccination with tumor-derived gp96 elicits a potent anti-tumor T cell response in mice and 
humans characterized by Th1 responses. However, priming of Th1 responses is precisely 
dependent on the dose of gp96 and immunization with a microgram (herein called low dose, LD) 
of gp96 elicits Th1/anti-tumor immunity. Intriguingly, a ten-fold higher dose of gp96 (high dose, 
HD) elicits a suppressive immune phenotype characterized by the preferential expansion of CD4+ 
Treg. Whereas CTLs are known for their ability to lyse infected and tumor cells, Treg shut down 
pro-inflammatory responses and are essential for preventing autoimmunity.  
The existence of a suppressive response driven by gp96 has been recognized since the 
initial identification of HSPs as tumor rejection antigens. Srivastava and colleagues appreciated 
that increased “units” of immunization no longer resulted in tumor protection (14). In fact, 
increased dose led to accelerated tumor growth in some experiments. Few attempts were made to 
further understand this phenomenon until over a decade later, demonstrated by Chandawarkar and 
colleagues. In agreement with previous findings, intradermal (i.d.) injection of 1 µg Meth A gp96 
elicited tumor-protective immunity, whereas injection of 10 µg Meth A gp96 did not (98). 
Furthermore, immunization with the higher dose of gp96 generated a suppressive response that 
could be transferred through the CD4+ T cell compartment. The same group later showed that 
suppression does not require source specificity per se, but an ongoing T cell response is necessary 
for full HD gp96-mediated suppression (99). A non-obese diabetes (NOD) mouse model was used 
in this study to show that timing of HD gp96 immunization was crucial for its outcome. The 
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autoimmune process of insulitis begins around 6 wk of age in NOD mice (100). Treatment of NOD 
mice at the onset of insulitis (6-8 wk) resulted in complete protection against disease. All NOD 
experiments were performed using liver- or pancreas-derived gp96 preparations, suggesting that 
the response is independent of antigen.  
 
The HD gp96 response has also been used for the prevention of autoimmune disease in 
mouse models of experimental autoimmune encephalomyelitis (EAE)(99) and rheumatoid arthritis 
(RA)(101), for the extension of allograft survival in mice and rats (102, 103), and for suppression 
of other Th1-mediated immune responses (104, 105). Kovalchin and colleagues found that 
treatment of mice with HD gp96 significantly improved survival of skin grafts in mice by about 
5-fold, even with major antigenic disparity (102). Similar findings from Slack et al. showed that 
donor-derived, but not recipient-derived, HD gp96 could prolong transplant survival (103). In this 
study, Lewis rats were immunized with HD gp96 derived from either Wistar or Lewis rats. Hearts 
from Wistar rats were then transplanted into Lewis rat recipients. Heart grafts in the group that 
received Wistar (donor) gp96 showed prolonged survival over those treated with Lewis (recipient) 
gp96. This suggests that gp96-bound alloantigenic peptides may be important in the context of 
transplant survival and is one of only a few studies which have shown any degree of specificity in 
the gp96 used to generate HD suppression. In the future, additional experiments should be 
performed using an antigen-specific model to confirm these findings. Finally, Li et al. have shown 
that HD liver-derived gp96 can limit immune hyperactivation in the liver using a model of ConA- 
and anti-CD137-induced liver injury (104). In addition to mammalian HSPs, a suppressive 
response hallmarked by Treg and IL-10 production can be achieved using microbial hsp70 (101). 
However, the mechanisms driving responses to microbial and mammalian HSPs may differ. Taken 
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together, HD gp96 suppression can be used to treat a wide range of conditions and is a viable 
option for the treatment of autoimmunity and transplantation.  
2.3.2 Mechanisms driving HD gp96-mediated suppression 
The apparent volte-face immune response elicited with LD versus HD gp96 immunization has 
until 2012 lacked a mechanistic explanation, despite the application of the phenomenon to 
ameliorate multiple pathological conditions in mice and humans. Table 4 provides a representative 
list of studies that have elucidated the regulatory responses elicited by immunogenic HSPs.  
 
Table 4: Summary of suppressive responses to HSP 
HSP type Targeted cells Mediators  Outcome Refer
ence 
mouse gp96 Treg (in vivo HD) IL-10, Ki67 increased Foxp3+ Treg; decreased 
liver inflammation 
(104) 
mouse gp96 Treg (in vivo HD) IL-10 decreased CTL activation (105) 
mouse gp96 in vivo HD - decreased EAE, diabetes (99) 
mouse, 
rat gp96 
in vivo HD - increased allograft survival (102, 
103) 
mouse gp96 mouse Treg (in vitro) NF-κB, IL-10, 
TGF-B, Foxp3 
- (104) 
tumor gp96 in vivo HD - decreased tumor immunity (98) 
tumor hsp70 MDSC (in vitro) STAT3 decreased T cell proliferation, IFNg 
production 
(2) 
MTB-hsp70 in vivo IL-10 decreased RA (101) 
MTB-hsp70 Treg (in vivo) IL-10 decreased L. monocytogenes killing (106) 
human gp96 human pDCs (in vitro) IL-8, NF-κB decreased monocyte maturation (1) 
 
As previously mentioned, HD gp96 immunization involves CD4+ T cells including Treg. 
Treg can drive suppressive immunity through many mechanisms, including: 1) production of 
suppressive cytokines such as IL-10, 2) sequestration of survival signal IL-2, 3) conversion of ATP 
to adenosine, and 4) inhibition of APCs via cytotoxic T-lymphocyte-associated protein-4 (CTLA-
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4) (107). Similar to CTLs, Treg are activated via MHC-T cell receptor (TCR) engagement and IL-
2 (108, 109), although in some cases this appears to be dispensable (110). In the same study 
demonstrating the efficacy of HD gp96 in treating liver inflammation, it was also revealed that 
suppression was specifically generated through Treg (104). HD gp96 immunization resulted in 29 
and 78% higher numbers of Treg in spleen and liver, respectively. These Treg were more highly 
active by Ki67 staining and expressed more Foxp3 and IL-10 compared with vehicle treated 
controls. In a similar study, mice were immunized with LD or HD gp96 conjugated to specific 
peptide (Kd restricted epitope)(105). Using tetramer to detect antigen-specific CTLs following 2 
rounds of immunization, Liu and colleagues detected fewer tetramer-positive CTLs and more Treg 
in HD versus LD immunized mice. Treg specificity was not measured, so whether these Treg are 
antigen specific or if they utilize a bystander suppression mechanism is unknown. Treg depletion 
by cyclophosphamide resulted in restoration of CTLs in this system. Thus there exists a balance 
between Treg and CTLs that is dependent on gp96 dose. Although gp96 immunization 
simultaneously activates both CTLs and Treg, CTL activation outpaces that of Treg following LD 
immunization, whereas the opposite is true in the context of HD gp96. Because a low level of Treg 
may be generated in response to LD gp96, it is also important to consider their role in suppressing 
tumor immunity. It is entirely possible that this low level of Treg activation in response to gp96 is 
critical for contraction of the pro-inflammatory phase, similar to situations of infection and 
pregnancy. Yan et al. showed that depletion of Treg following LD gp96 treatment greatly 
enhanced tumor rejection compared with either treatment alone (111). It was concluded from this 
study that the efficacy of gp96 immunization in clinical trials could be improved by blocking Treg. 
Taken together, it is clear that CD4+ T cells, particularly Foxp3+ Treg, are the driving force behind 
HD gp96 suppression.  
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 Comparatively little is known about the effects of HD gp96 on the phenotype of APCs. 
Increasing the concentration of gp96 in vitro from 50 µg/ml to 250 µg/ml enhances NF-κB 
signaling in APCs (62), yet the functional outcome of this was not tested. It is possible that 
targeting an alternate APC type may result in activation of suppressive immunity. pDCs are a 
subset of DCs with diverse functions, and are mainly involved in anti-viral responses and induction 
of Treg under certain contexts including cancer (112, 113). These cells are highly prevalent in 
tumors and tumor draining lymph nodes and may contribute to the suppressive tumor 
microenvironment (4). Human pDCs bind gp96 and activate the NF-κB pathway in a CD91-
dependent manner (1). Moreover, gp96-stimulated pDCs can limit the maturation of monocytic 
macrophages and their production of pro-inflammatory cytokines IL-6, IL-8, and TNF. Whether 
pDCs play any role in activating Treg in response to gp96 was not tested in this study. pDCs do 
not, however, increase expression of immunosuppressive enzyme indoleamine 2,3 dioxygenase 
(IDO) in response to gp96 (104).  
There is also a potential role for MDSCs in generating a suppressive response to hsp70. 
MDSCs are a heterogeneous population of cells from the myeloid lineage that robustly expand 
under chronic inflammatory conditions such as cancer and infection. MDSCs are distinct from 
other myeloid cells in that they possess strong immunosuppressive properties (114). Hsp70-
positive tumor-derived exosomes (TDEs) harvested from the supernatants of tumor cells can bind 
to MDSCs in vitro and promote suppressive activity via STAT3 (2). When TDE-stimulated 
MDSCs were co-cultured with OVA-specific CTLs, T cell proliferation and IFNγ production were 
blunted. This activity was determined to be hsp70-specific, since TDEs derived from hsp70-
deficient tumor cells did not activate this pathway. Treatment of MDSCs with recombinant hsp70 
alone was sufficient to trigger this suppressive phenotype as well.  
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Clearly, APC responses to HSPs are dependent upon the type of APC which is engaged. 
The fact that both pDCs and MDSCs can bind to HSPs, initiate suppressor functions, and are 
prevalent in tumor-bearing hosts is a concern for use of HSPs cancer immunotherapy. A further 
understanding of how these APCs respond to HSPs is therefore required to improve upon clinical 
trials using HSPs. 
2.3.3 HSPs in autoimmunity 
Because of the immunogenic properties of HSPs, it was hypothesized that local and continuous 
stimulation by extracellular HSPs could result in chronic immune activation and inflammation. 
Humans with RA have elevated gp96 and hsp70 in the synovial fluid of inflamed joints (115-117). 
Furthermore, treatment of fibroblasts with synovial fluid from RA patients resulted in increased 
surface hsp70. Surface expression of hsp70 is known to occur on stressed cells to make them more 
vulnerable uptake by CD91 (78, 118). It is possible that elevated hsp70 in the synovial fluid and 
surface expression of hsp70 by fibroblasts contributes to the local inflammatory response by 
binding its receptor and triggering cytokine release. 
Whether vaccination with self- or even bacteria-derived HSPs can elicit an autoimmune 
response in the host was a primary concern when HSP immunotherapy was first introduced. Yet 
in both rodents and humans, autoimmunity following HSP treatment has never been recorded 
(119). Treatment of rats with Mycobacterium tuberculosis (MTB)-derived hsp70 (MTB-hsp70) 
prior to adjuvant-induced arthritis actually prevents autoimmune sequelae (119, 120). Pre-
treatment of mice with MTB-hsp70 can also suppress T cell responses to Listeria monocytogenes 
via IL-10 production (106). In both cases, these suppressive responses seem to be directed toward 
the HSP molecule itself rather than peptides bound by it. Whereas RA patients have a persistence 
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of hsp70 in the synovial fluid, immunization provides a fixed bolus of HSP that is taken up within 
a 48-hour period (61). The level of HSP persistence and availability to APCs may explain the 
apparent discrepancy between these studies. 
2.4 DNA METHYLATION AS A MECHANISM FOR TRANSCRIPTIONAL 
REGULATION OF IMMUNE RESPONSES 
With the development of the Human Genome Project and next generation sequencing, interest in 
genomic regulation has exploded over the last decade. Yet genomic sequences are only a minute 
part of the picture. We can now appreciate that many other factors are involved in transcriptional 
regulation, particularly epigenetic modifications. Epigenetic marks include but are not limited to: 
post-translational modification of histone tails, chromatin packaging, non-coding RNAs 
(ncRNAs), and DNA methylation. This section will focus on DNA methylation, since in certain 
cells DNMT1 can work in tandem with active NF-κB (121), an important moderator of immune 
responses. Thus DNA methylation may be a viable mechanism through which HSP responses are 
arbitrated. 
2.4.1 DNA methylation is an epigenetic mark that regulates gene expression and histone 
modification 
DNA methylation is the only epigenetic mark known to directly modify DNA via covalent 
attachment of a methyl group to the C5 position of cytosine residues. It preferentially occurs on 
CpG dinucleotide sequences, although methylation has been detected on non-CpG in embryonic 
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stem cells, adult mammalian neurons, MTB-infected macrophages, and human CD4+ T cells (122-
125). Presumably, non-CpG methylation has been detected only recently due to advances in our 
ability to measure methylation at single base resolution by bisulfite PCR. Overexpression of 
DNMT3a, one enzyme responsible for catalyzing DNA methylation, can result in higher frequency 
of non-CpG methylation of the Ifng promoter in HEK 293 cells (122). Many roles have been 
classically attributed to DNA methylation, including imprinting and X-chromosome activation, 
silencing of transposons and repeat elements, and repression of tissue-specific genes (126). All are 
examples of established epigenetic marks that persist even through cell division. This is partially 
due to an abundance of methylated cytosines (hypermethylation) flanking CpG islands (127). It 
was therefore assumed that DNA methylation provided a stable and often permanent mechanism 
of repression that was not amenable to environmental cues. Recent data has challenged this notion, 
and a dynamic role for DNA methylation in translating environmental signals into a functional 
outcome in cells has been appreciated (128, 129). One such example was demonstrated by Meaney 
and Szyf, who observed structural and methylation changes at the Gabra1 promoter of rat pups 
was dependent on the amount of maternal care received by the pups, as measured by licking (128). 
Gabra1 encodes for the γ-aminobutyric acid receptor (GABAAR). GABAAR is widely expressed 
in the central nervous system and upon binding of its ligand, results in an inhibitory effect on 
neurotransmission. Additionally, Guo et al performed genome-wide DNA methylation studies in 
forebrain cells from mice given electroconvulsive stimulation (to activate neurons) and compared 
them to mice that did not receive treatment. At 0 hr, 4 hr, and 24 hr following treatment, mouse 
neurons were harvested for analysis. In as little as 4 hr, ~1.4% of all CpGs were either 
demethylated or de novo methylated (130). Many of these changes were stable over at least a 24 
hr period. Specific examples in the context of the immune system, including responses to infection 
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and cellular activation, are discussed in Section 1.4.3 of this thesis. Changes to the DNA 
methylome in these studies occurred in as little as 20 minutes to several hours following treatment, 
suggesting that methylation of certain genes may occur on a shorter time scale than previously 
proposed. 
 Methylation of promoters results in suppression via several mechanisms: 1) blocking of 
transcription factor binding by the methyl group itself, 2) recruitment of methyl-binding domain 
(MBD)-containing proteins that physically block transcription factors (131), and/or 3) recruitment 
of histone deacetylases (HDACs) which promote chromatin condensation (132-134). Whether the 
relationship between DNA methylation and gene expression is causal or associative has been 
debated. In some cases, it may be that methylation is simply a mark used in daughter cells to 
instruct them to shut down expression using so-called “epigenetic memory” (135). It seems that 
these events are dependent upon context and genomic location.  
A growing body of literature supports the notion that DNA methylation is intricately tied 
to histone modifications. Histones are proteins that package DNA into structures called 
nucleosomes, which wind DNA into either an open (euchromatin) or closed (heterochromatin) 
confirmation. Post-translational modification of histone tails can impact the status of chromatin 
accessibility at nucleosomes. In general, acetylation of lysines on histones H3 and H4 is associated 
with transcription, whereas the transcriptional outcome of lysine methylation may vary depending 
on the site (136). MBD proteins have been shown to bind HDACs and form a repressor complex 
within promoter regions (134, 137, 138). In fungi and cancer cells, preexisting H3K9 methylation 
or the histone methyltransferases themselves can interact with DNMT3a and promote methylation 
of target genes (139, 140). These findings were confirmed in a mammalian system using mice 
deficient in Suv39h, a histone methyltransferase that catalyzes H3K9 methylation. In this study, 
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Suv39h was required for DNA methylation at pericentric, but not centromeric, repeats (141). 
EZH2, a functional component of the PRC2, is known to catalyze methylation at H3K27 (142) and 
can also interact with DNMT (143). Its methylation activity is associated with transcriptional 
repression through formation of heterochromatin. Methylated H3K27 acts as a docking point for 
a group of proteins responsible for repressing gene transcription, including Polycomb proteins 
(142). In fact, Polycomb-mediated H3K27 methylation was found to predict methylation of genes 
in tumor cells (144). It is thought that this allows for formation of “epigenetic memory” in dividing 
cells. Clearly there exists intricate communication between epigenetic machinery to regulate 
transcriptional activity.  
2.4.2 Regulation of DNA methyltransferases 
DNA methylation is catalyzed and maintained by a family of enzymes called DNMTs. In almost 
all known cases, S-adenosyl methionine (SAM) is used as the methyl donor and involves DNMT-
associated factors. SAM is produced in mitochondria of cells and thus may be impacted by the 
metabolic state of the cell. In fact, when rats were fed a diet enriched in folate, a vitamin that acts 
as a methyl donor, they were found to have increased levels of DNA methylation in their colon 
and liver compared with rats given a folate-free diet (145). Similar studies performed in mice 
showed that folate-deficient diet led to impaired vessel function and changes in methylation in the 
brain (146). It is also possible that the nutrient-poor tumor microenvironment can have an impact 
on DNA methylation changes associated with cancer (147). 
DNMTs are ubiquitously expressed and their expression is upregulated upon entering the 
cell cycle. Its location at the replication fork of DNA and its preference for hemimethylated DNA 
is in agreement with its role as a maintenance methyltransferase. The mammalian DNMT family 
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includes four members: DNMT1, DNMT3a, DNMT3b, and DNMT3L. All mammalian DNMTs 
have some capacity to maintain methylation, although DNMT1 is predominantly responsible for 
maintenance during cell replication and is the most abundant DNMT in adult mammalian cells 
(148). During embryogenesis and in response to certain stimuli, DNMT3a and 3b are the dominant 
de novo methyltransferases. They can methylate hemimethylated and non-hemimethylated DNA 
equally well (149). A fourth protein, DNMT3L, is structurally similar to DNMT3 and is required 
for proper methylation but is inactive on its own (150). Some studies have indicated that DNMT1 
associates with DNMT3 to initiate de novo methylation and that DNMT3 contributes to 
maintenance despite its lack of preference for hemimethylated DNA (151, 152). Thus, cooperation 
between all DNMTs is required for proper methylation. 
2.4.3 DNA methylation in the immune system 
In contrast to histone modification, how immune cells utilize DNA methylation to process 
environmental cues is not well studied. A growing body of evidence suggests that the DNA 
methylome of cells is highly susceptible to manipulation following signal transduction (129) and 
infection with bacteria (125, 153), viruses (154), or protozoa (155). Two independent groups have 
shown that infection of human primary DCs or a monocytic cell line with MTB leads to dynamic 
remodeling of the methylome (125, 153). Pacis et al. showed that differential methylation was 
associated with changes in activating histone marks (measured by ChIP-seq) and transcription 
(measured by RNA-seq)(153). However, a paired time-course analysis of DNA methylation and 
gene expression did not suggest that demethylation preceded expression. The authors did not 
measure whether 5-hydroxymethylcytosine (5hmC), the rate-limiting step of demethylation, 
preceded expression. Interestingly, Sharma and colleagues observed non-canonical genome-wide 
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methylation changes at non-CpG residues in MTB-infected macrophages (125). Considering many 
of the detected regions were found in ncRNA genes, including lncRNA, miRNA, piRNA, and 
snoRNA, it is thought that MTB infection specifically targets regulatory regions of the genome. 
Pathogens may also seize control of host epigenetic machinery to deter pathogen recognition. 
Langerhans cells use E-cadherin to navigate stratified epithelium and allow for detection of cancer-
associated viruses, including human papillomavirus (HPV). It appears that HPV E7 protein 
directly associates with DNMT1 to drive repression of E-cadherin and contribute to HPV 
persistence (154). Finally, methylome remodeling in Leishmania donovani-infected macrophages 
leads to repression of host responses (155).  
Manipulation of the T and B cell methylome has also been reported, particularly in naïve 
versus effector populations. Early work in this field showed that treatment of primary mouse CD8+ 
T cells with DNMT inhibitor 5-azacytidine (5-azaC) resulted in a 25-fold increase in IFNγ 
expression and a 14-fold increase in IL-3 expression (156). Activation of T cells using anti-CD3/28 
stimulation resulted in site-specific demethylation of Ifng and Il3 promoters. It was later shown by 
the same group that demethylation of Ifng is heritable in CD44high memory CD8+ T cell clones 
(157). Using a P14-transgenic mouse model with a knock-in TCR specific for lymphocytic 
choriomeningitis virus (LCMV) epitope GP33-41, Scharer et al. observed dynamic methylome 
alteration of CD8+ T cells after in vivo LCMV infection (158). Biologically relevant gene 
promoters such as Gzmb and Zbtb32 were demethylated in effector T cells compared with naïve 
controls. Demethylation of key genes appears to poise the activated T cells for rapid expression of 
effector molecules. This is not unlike memory CD4+ T cells, which demethylate Il13, Il17a, and 
Ccl3, all of which can be promptly expressed upon reencountering antigen (159). Several groups 
have reported that the IL2 promoter is demethylated in memory T cells for the same reason (160, 
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161). Engagement of the TCR by ligands that induce strong signaling favors DNMT1 activation 
via a glycogen synthase kinase (GSK3)-dependent pathway (162). This results in methylation and 
repression of Foxp3 in conventional T cells (Tcon). Finally, plasma cell and germinal center B cell 
differentiation is also dependent on DNA methylation (163, 164). Taken together, it is quite clear 
that DNA methylation plays an emerging role in the immune system as a translator of 
environmental cues to control responses to infection, cytokine stimulation, and cellular activation.  
2.5 INTRODUCTION SUMMARY 
 
The central hypothesis of this thesis is that specific subsets of APCs may respond to gp96 in 
fundamentally different ways, which influences their ability to activate T cells. I propose that 
this is a result of epigenentic differences in these populations. In this thesis, Chapter 1 will 
focus on the expression of CD91 on various DC subsets and determine which interact with gp96 
following LD or HD gp96 immunization. Uptake of gp96 at LD has previously been characterized 
by our lab, demonstrating that CD11b+CD11c+ cDCs are required for cross-priming of T cells (61). 
However, it is possible that a different APC subset is targeted at HD, given that stimulation of 
various DC types in vitro may lead to either a pro- or anti-inflammatory phenotype. There may 
exist an active mechanism driving accessibility of gp96 for different APC subsets. Thus, 
experiments in Chapter 2 will further dissect the mechanisms used by regulatory DCs identified in 
Chapter 1 to understand the HD suppressive response. To this effect, we have observed that DNMT 
activation in gp96-stimulated cells leads to methylome remodeling in responsive APCs. In pDCs, 
remodeling occurs on the gene body of Nrp1. This event triggers expression of Nrp1 and facilitates 
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pDC-Treg stabilization. Finally, Chapter 3 will focus on signaling mediators downstream of CD91 
and how signaling events in APCs drive cross-talk with NK cells in response to gp96.  
 
 
 34 
3.0  CHAPTER 1: CLASSIFICATION OF APCS ASSOCIATED WITH HIGH DOSE 
GP96 SUPPRESSION 
 
PREFACE 
 
Most of the data in this chapter has been published in Nature Communications, of which I am first 
author (79). Figures 4A-C, 5, and 7-10 are copyright (2017) Nature Publishing and is distributed 
under a Creative Commons CC-BY license. This information is presented here and expanded upon 
by the author. 
3.1 RATIONALE 
It is known that cDCs are required to take up HSP at LD to elicit immunity (61). Additionally, the 
response generated by these APCs has been widely studied in vitro using bone marrow-derived 
DCs (BMDCs), peritoneal exudate cells (PECs), and various DC- and macrophage-like cell lines. 
Whether these APCs are responsible for generating the response observed with HD gp96 has not 
been considered.  
There are two possibilities to explain the innate response to HD gp96: 1) an alternate APC 
subset gains access to gp96 at HD, or 2) saturation of the receptor results in a phenotype switch in 
responding APCs. The latter is less likely, given that mediators of the LD response including 
maturation markers and NF-κB continue to elevate in DCs given increased concentrations of gp96. 
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It is known that human pDCs, when given gp96 in vitro, can bind gp96 with similar efficiency as 
monocytes (1). Human pDCs do not undergo maturation in response to treatment and instead 
inhibit activation of monocytes. This suggests that variant responses can be achieved depending 
on the APC subset that is targeted; however, whether pDCs are targeted following HD gp96 
immunization was not tested in these studies.  
We have followed up on these studies and have observed increased uptake of fluorescently 
labeled gp96 by pDCs following HD gp96 immunization in vivo. We have also found that CD91 
is indispensable for this response, similar to LD immunization. Intriguingly, the HD response is 
potent enough that it is not overcome with the addition of IL-12 into the system. The work 
presented herein is essential not only for developing potential immunotherapy for autoimmunity, 
but will also improve our understanding of how suppressive responses to HSPs are elicited in 
general. In turn, this knowledge can help improve upon current clinical trials using HSPs for tumor 
immunotherapy, since pDCs are prevalent within tumor-bearing hosts.  
3.2 RESULTS 
For the experiments presented in this thesis, homogenous preparations of gp96 were isolated from 
murine liver. Gp96 purity (Figure 2A,B) and biochemical activity (Figure 2C) were tested to 
ensure that the properties of gp96 were preserved. For in vivo gp96 tracking experiments, gp96 
preparations were fluorescently labeled with Alexafluor 488 (gp96A488). Uptake of gp96A488 can 
be detected by flow cytometry and confocal microscopy (61).  
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Figure 2. Characterization of purified murine gp96. 
Characterization of purified murine gp96. Gp96 preparations were tested for purity and biochemical 
activity to ensure quality of protein. A-B. gp96 was analyzed by 10% SDS-PAGE following staining 
with Coomasie blue (A), and by immunoblotting with a gp96 specific monoclonal antibody (B). C. 
ATP hydrolysis by gp96 was assessed. Gp96 was incubated at 37
o
C for indicated time period with 
ATP. Following addition of malachite green, µM ATP hydrolyzed was calculated from a standard 
curve. MSA was used as a negative control.  
3.2.1  CD91+ DCs are required for gp96-mediated immune suppression 
We tested whether CD91 was required to generate immune suppression in a murine model of 
cancer when mice were immunized with HD gp96. Towards this goal, we have generated mice 
that are selectively deficient in CD91 expression on CD11c+ cells (CD91f/fCD11ccre) and 
characterized their phenotype. These mice have normal numbers of APCs (including cDCs and 
pDCs), T cells, and B cells at steady state (26) and were used in a gp96-mediated suppression 
assay (Figure 3A). CD91f/fCD11ccre or wild type littermates (CD91f/f) were immunized with 
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Figure 3. HD gp96-mediated immune-regulatory response requires CD91+ DCs. 
A. The experimental set up to test the role of CD91
+
 DCs in HSP-mediated immune-regulatory response. 
Immunization was carried out using irradiated D122 (Groups 1,3,4,5) or control PBS (Group 2). Suppression of anti-
tumor immunity, elicited by irradiated D122, was mediated by HD gp96 treatment (Group 3) or control PBS (Groups 
1&2). LD gp96 and MSA treated mice were included as negative controls. All mice were challenged with D122 and 
tumor growth was monitored. B. Tumor growth in wild type littermates (CD91
f/f
). C. Tumor growth in mice lacking 
expression of CD91 in CD11c
+
 cells (CD91
f/f
CD11
cre
). Shown is the average tumor diameter ± SEM. n=3-5/group, 
data are from 1 representative experiment of 3 independent experiments. [The value of SEM in Group 3 is too small 
to be seen in the graph]. 
 
irradiated tumor cells. Mice were treated with HD gp96 followed by tumor challenge. Groups that 
received LD gp96 or mouse serum albumin (MSA) instead of HD gp96 were included as negative 
controls. Tumor growth was monitored in all mice by measurement of tumor in two perpendicular 
axes. Regardless of CD91 expression, mice immunized with irradiated tumor cells only (Group 1) 
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were able to reject a subsequent challenge with that tumor (Figure 3B,C), while unimmunized mice 
developed progressive tumors (Group 2). In a separate cohort (Group 3), immunized mice were 
administered HD gp96 7 days prior to tumor challenge. Vaccinated CD91f/f mice were unable to 
limit tumor growth following HD gp96 administration (Figure 3B). However, similarly treated 
CD91f/fCD11ccre mice remain protected against challenge (Figure 3C). These results indicate that 
CD91+CD11c+ APCs were necessary for HD gp96-mediated suppression of protective anti-tumor 
immunity in vaccinated hosts. This observation was also dependent upon the dose of gp96 since 
mice treated with LD gp96 failed to suppress anti-tumor immunity, consistent with previous 
reports.  
3.2.2 HD gp96 suppression cannot be overcome by IL-12 
In all models of LD and HD gp96 immunization that have been tested, T cells are indispensable 
for immunity. IL-12 production by APCs is important for differentiation of naïve T cells into 
Th1 cells and stimulates IFNγ production by lymphocytes (165-167). IL-12 is also known to 
be released upon HSP immunization and co-administration of HSP + IL-12 enhances anti-
tumor immunity (60, 130). Given the important role for this cytokine, we tested whether 
exogenous administration of IL-12 could counteract the effects of HD gp96. For these 
experiments we utilized the same model described in Section 2.2.1 and Figure 3A, with an 
additional group that was given IL-12 via the i.p. route every day for 6 days (Figure 4A). All 
mice used in this experiment were CD91f/f, mimicking wildtype. Intriguingly, this did not seem 
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Figure 4.  IL-12 alone is not sufficient to overcome HD gp96-mediated immune-regulatory 
response. 
A. The experimental set up to test the role of IL-12 in HD immunity. Immunization was carried 
out using irradiated D122 (Groups 2-4) or control PBS (Group 1). Suppression of anti-tumor 
immunity, elicited by irradiated D122, was mediated by HD gp96 treatment (Groups 3&4) or 
control PBS (Groups 1&2). Group 4 mice were given daily treatments of IL-12 i.p. for 7 days prior 
to challenge. All mice were challenged with D122 and tumor growth was monitored. B. Tumor 
growth in mice given IL-12 was equivalent to growth in Group 3. Shown is the average tumor 
diameter ± SEM. n=3-5/group, data are from 1 representative experiment. 
 
to have an effect on overall tumor growth (Figure 4B). Tumors grew with HD gp96 treatment 
regardless of IL-12, suggesting that the HD gp96 response is not overcome by IL-12. This may be 
due to a variety of factors, including lack of antigen specificity in our model or the need for a 
combination of cytokines in addition to IL-12. It is also possible that the level of Treg-driving 
cytokines and other signals may be high enough to signal the contraction phase of the immune 
response, regardless of IL-12 levels.  
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Figure 5. DC numbers following LD and HD gp96 immunization. 
A,B. Mice were immunized intradermally with LD or HD gp96 or given PBS. 
After 18 hr, draining lymph node (A) and spleens (B) were harvested and absolute 
numbers of CD11b
+
 and CD11c
+
 populations were analyzed. n=5/group, data are 
from 1 representative experiment of 3 independent experiments performed.  
3.2.3 Dynamic cellular changes and alternative interactions of gp96 with DC populations 
at HD 
We have previously shown that immunization with LD gp96 leads to priming of anti-tumor 
immune responses. This is in stark contrast to responses elicited by HD gp96 shown here. To 
understand this operational dichotomy in greater detail, we investigated the CD91+CD11c+ cells 
necessary for gp96-mediated immune responses. We first analyzed the two major APC types 
within this population, both of which express CD91 (61). Mice were immunized with LD or HD 
gp96 or administered PBS. Lymph nodes or spleens were isolated after 18 hr and cells were 
analyzed by flow cytometry. The total number of CD11c+CD11b+ cells and CD11c+CD11b- cells 
in the lymph nodes of immunized mice were increased 2-3 fold over samples from unimmunized 
mice regardless of whether mice were immunized with LD or HD gp96 (Figure 5A). Such 
increases were not observed in spleen samples (Figure 5B). Thus, comparative differences in the 
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number of cells in these two populations in lymph nodes by themselves could not account for 
altered immune responses observed after immunization with LD vs HD gp96.  
We next examined the APCs that engage gp96 following immunization at either dose. 
Gp96 was labeled with A488 and LD or HD gp96A488 was administered to mice. Draining lymph 
nodes were examined by flow cytometry after 8 hr and analyzed for A488 fluorescence (Figure 
6A).  CD11c+CD11b+ and CD11c-CD11b+ cells were preferentially engaged by gp96 at both doses. 
For CD11c+CD11b+ cells this appeared unrelated to the dose of gp96 used for immunization 
(Figure 6B). Interestingly, CD11c-CD11b+ cells made up a smaller percentage of gp96A488+ cells 
at HD compared to LD (Figure 6B). Of the APCs that were detected in this study, pDCs 
(CD11clow/+CD11b-B220+PDCA+) were the only subset that made up a larger percentage of 
gp96A488+ cells at HD (Figure 6B). We thus focused on pDCs for two reasons; first, this cell 
population incorporated more gp96 at HD versus LD, and second, pDCs are known for their 
immunosuppressive properties in certain contexts. Upon further analysis the number of pDCs that 
were gp96A488+ increased ~5-fold between LD and HD (Figure 6C,D). 
3.2.4 pDCs express CD91 but do not mature when exposed to gp96 
We next wanted to confirm CD91 expression in pDCs from CD91f/fCD11ccre mice, given the low 
CD11c expression in these cells. Lymph nodes were first isolated from CD91fl/flCD11ccre or 
CD91fl/fl mice and analyzed for cDCs and pDCs. We show for the first time that CD91 expression 
was undetectable on pDCs isolated from CD91fl/flCD11ccre mice and its deletion was as complete 
as that for cDCs (Figure 7A). Interaction of gp96 with different populations of DCs is strictly 
correlated with, and dependent on, the levels of CD91 that they express. This correlation is also 
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true when the gp96-mediated phenotype is measured in DCs. pDCs expressed CD91 to similar 
levels seen in cDCs (Figure 7A). CD91 levels did not significantly change on either population 
following immunization of mice with any dose of gp96 (Figure 7B).  
 
Figure 6. Preferential targeting of pDCs at HD gp96. 
Mice were immunized with LD or HD gp96A488. Lymph nodes were harvested 8 hr later. Lymph node cells were 
analyzed for A488 positivity by flow cytometry using CD11b, CD11c, B220, and PDCA cell surface markers. A-B. 
Total A488
+
 were gated and the makeup of this population was analyzed using DC markers. C-D. The percent of pDCs 
that are A488
+
 is shown. Data are from 1 representative experiment of 3 independent experiments. 
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Figure 7. cDCs and pDCs express similar levels of CD91. 
A. Histograms depict CD91 staining within representative lymph node cDC (CD11b
+
CD11c
+
) or pDC 
(CD11c
low/+
CD11b
-
 B220
+
PDCA1
+
) populations from naïve CD91
f/f 
or CD91
f/f
CD11c
cre 
mice. B. Mice were 
immunized with LD or HD gp96 or given PBS. At 18 hr post-immunization, lymph nodes were harvested and stained 
for CD91 in pDCs and cDCs. Shown are CD91 MFI values for each population. n=5/group, data are from 1 
representative experiment of 3 independent experiments.  
 
Maturation is a hallmark of the cDC response to gp96 and other HSPs. This is mainly 
driven by NF-κB activation following HSP-CD91 binding. It has been previously shown, however, 
that although NF-κB translocation to the nucleus occurs in human pDCs in response to gp96, they 
do not upregulate expression of maturation markers known to be expressed by cDCs including 
CD86 and MHC (1). To test whether murine pDCs exhibit a similar phenotype, we isolated 
BMDCs (representing cDCs) and spleen pDCs and stimulated them with gp96 in vitro. pDCs were 
given CpG as a positive control. After 24 hrs, cells were harvested and analyzed by flow cytometry 
A. B. 
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for expression of costimulatory and maturation markers. Similar to previous studies, in response 
to gp96 BMDCs upregulated CD86 and MHC class II, but not CD80 (Figure 8A). In contrast, these 
markers did not increase on gp96-stimulated pDCs (Figure 8B).  
 
Figure 8.  cDCs undergo maturation in response to gp96, whereas pDCs remain immature. 
cDCs (A) or pDCs (B) were stimulated with HD gp96 for 24 hours in vitro and then analyzed for maturation markers 
CD80, CD86, and MHC II by flow cytometry. CpG-stimulated pDCs were included as a control for pDC maturation. 
Average MFI is shown for each marker.  
3.3 DISCUSSION 
To briefly summarize the findings of this section, CD91 is required for generation of suppressive 
HSP responses and addition of exogenous IL-12 into the system is not sufficient to overcome the 
HD response. CD91 is expressed by multiple APC types including both cDCs and pDCs, making 
each population a potential target at both LD and HD gp96. However, pDCs are the only APC 
subset whose gp96 uptake is greatly increased following HD immunization. Unlike cDCs, pDCs 
do not undergo maturation in response to gp96, further supporting their putative role in suppressive 
responses. Chapter 2 will further discuss the pDC phenotype elicited by HD gp96. 
A. 
B. 
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3.3.1 Effects of IL-12 on the tumor microenvironment 
Our lab has shown that CD91 is necessary and sufficient for HSP-mediated cross-priming of CTLs 
both in vitro and in vivo. HD suppression also appears to be CD91-dependent in our models. It is 
rather surprising that daily treatment of mice with IL-12 was not adequate to overcome HD 
suppression. It is entirely possible that there are other cytokines in addition to or instead of IL-12 
that drive this response. The RAW264.7 macrophage cell line and peritoneal macrophages express 
modest levels of IL-12p70 when treated with gp96, hsp70, and calreticulin (62, 70). Other pro-
inflammatory cytokines known to enhance effector lymphocyte function that are released in 
response to HSPs include IL-6, CXCL10 , IL-1β, and TNF-α. It may be that some combination of 
these must be present to overcome suppression. 
   IL-12 in the tumor microenvironment leads to augmented production of IFNγ by CTLs and 
NK cells and can enhance their cytotoxic capabilities (168). Immunotherapy using tumor antigen-
loaded DC in combination with recombinant IL-12, or antigen-loaded DCs which overexpress IL-
12, was shown to greatly improve MCA205 tumor rejection (169). Treatment with IL-12 alone or 
with spleen peptide-pulsed DC with IL-12 did not significantly increase tumor killing. It is possible 
that in our HD model, lack of antigen-specific peptides does not provide any additional efficacy 
of IL-12 treatment. To address this, these experiments should be repeated using OVA-expressing 
tumor cells and OVA-bound gp96 to create a defined, antigen-specific system. 
3.3.2 Implications of gp96 release by tumors and traumatic wounds 
Under certain physiologically relevant conditions, cells may release HSPs into the extracellular 
space. This occurs even at steady state, as soluble hsp70 can been detected in the serum of healthy 
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humans (170). This may allow for some cross-recognition of HSPs in the peripheral circulation. 
Extracellular HSPs have been detected at higher levels in some disease states, such as in 
bronchoalveolar lavages of humans with lung inflammation (171), synovial fluid of RA patients 
(115, 116), and tumors (172, 173). The immune outcome of local HSP release depends on the 
microenvironment, the local APCs, and presumably the amount of HSP that is being released.  
Active secretion of hsp70 has been detected in human prostate tumor cell line PC-3 and 
human colorectal tumor line HRT-18 (172). Low levels of extracellular hsp70 can also be detected 
in untreated solid tumor stroma formed after in vivo challenge with these cell lines. Induction of 
tumor necrosis by cryo-thermal therapy significantly increases hsp70 within the tumor 
microenvironment and serum of tumor-bearing mice (173). When DCs were treated with serum 
from cryo-thermal treated mice, expression of maturation markers CD86 and MHC II was 
significantly increased. DC maturation was hsp70-dependent since depletion of hsp70 from serum 
did not induce expression of these molecules. Additionally, Kottke et al. showed that intraprostatic 
injection of hsp70-overexpressing adenovirus followed by damage of prostate cells results in 
release of hsp70, uptake by immune cells, and increased IL-6 and TGF-β production (174). 
Subsequently, auto-reactive Th17 cells are activated and are cross-reactive against prostate cancer 
cells. Thus, mice treated in this way are better protected against challenge with prostate tumor 
cells. Although not an example of natural release by tumors, this is in agreement with studies from 
our lab showing activation of Th17 cells following gp96 immunization (62).   
There are also examples of higher doses of local HSP release following a large volume of 
cell death. The microenvironment of a trauma wound is one such example. Due to vascular 
disruption, wounded tissue tends to be oxygen and nutrient deficient. Jayaprakash et al. have 
shown that hsp90 is a key mediator of wound healing in the hypoxic wound microenvironment 
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(175). Hypoxia induced high intracellular expression of the hsp90β isoform which stabilizes CD91 
at the cell surface. Concomitantly, hsp90α was secreted in large amounts, which then bound to 
CD91 and promoted wound healing. Renal tubule cells subjected to hypoxic environments have 
also been shown to increase expression of gp96 (176), although temporal expression was not 
tested. CD91 can promote skin cell migration in response to extracellular hsp90, and thus may be 
important for responses to hypoxia and wound healing (177). Furthermore, CD91 is known to be 
highly expressed by trophoblasts, placental decidua, and decidual DCs, and its expression is altered 
by the presence of progesterone during pregnancy (178). It is possible that the suppressive response 
to HSPs was evolved to protect the host against cytokine storm in response to traumatic wounds, 
to promote wound healing, or possibly to protect the developing fetus during pregnancy. Taken 
one step further, we hypothesize that within the microenvironment of large tumors, increased local 
release of HSPs may contribute to immune suppression. 
 
3.3.3 Tolerogenic pDCs in allograft transplantation and cancer 
I present evidence in this section that pDCs increase interaction with gp96 from LD to HD by ~5-
fold. Gp96+ cells are mainly comprised of CD11b and CD11c expressing cells, as shown in 
previous work (61) and the data presented here. Comparison between gp96+ populations revealed 
that pDCs are the only APC population we tested that make up a higher percentage of gp96+ cells 
at HD compared with LD (Figure 6B). This is in agreement with our finding that a CD11b-CD11c+ 
DC population is preferentially targeted with HD gp96 immunization.  
pDCs are classically associated with anti-viral responses, because they produce 200-1000 
times more type I IFNs than any other cell type in response to microbial challenge (179). In 
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response to inflammation, pDCs are recruited from their steady state locations (blood, thymus, and 
secondary lymphoid organs) to the site of inflammation and associated draining lymph nodes. 
Mounting evidence suggests that pDCs can act as professional APCs, particularly after TLRs or 
endocytic receptors are engaged. Interestingly, ligation of certain endocytic receptors on pDCs 
such as BDCA-2 and DCIR actually impairs IFN production while increasing their ability to 
present antigen (180-182). The maturation status of pDCs does not seem to dictate their interaction 
with T cells as reliably as mature cDCs do. While steady state immature pDCs almost exclusively 
promote tolerance, mature pDCs may promote either pro- or anti-inflammatory responses 
depending on the local environment.  
For the purposes of this Discussion, I will focus on the suppressive properties of pDCs and 
their role in promoting tolerance to allografts and tumors, as these are two situations in which HD 
gp96 is relevant. Using a specific antibody (called YAe) to recognize donor-derived MHC I-Ed 
peptide presented by recipient MHC I-Ab, Ochando and colleagues observed that a population of 
CD11c+B220+PDCA+Gr1+CD19- pDCs are a main source of alloantigen presentation within a 
cardiac allograft (183). YAe+ pDCs migrate to lymph nodes in tolerized mice, yet in mice that 
rejected the transplants YAe+ pDCs were largely detected in the spleen. This was mainly due to 
the fact that YAe+ pDCs colocalized with T cells in the lymph node where they facilitated the 
development of Treg. In another study, pDCs were shown to express high levels of gut-homing 
chemokine receptor CCR9 (184). These pDCs are immature (low levels of CD40, CD80, CD86 
and intermediate levels of MHC II), and upon maturation they lose expression of CCR9. Adoptive 
transfer of OVA-loaded CCR9+ pDCs into recipient mice was correlated with a loss in OVA+ CTL 
proliferation and a strong induction of Foxp3+ Treg. CCR9+ pDCs were also sufficient to protect 
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mice from lethal graft versus host disease. pDCs capable of inducing IL-10 producing Treg have 
also been identified in humans (185). 
pDCs are found in abundance within the tumor microenvironment and tumor draining 
lymph nodes of some cancers. Whether pDCs contribute to tumor rejection or persistence is an 
area of debate and may depend on the type of tumor. In human melanoma, pDCs within the primary 
tumor and draining lymph nodes have defects in maturation and contribute to insufficient T cell 
priming (186). In a murine model of melanoma, pDCs in the tumor-draining lymph nodes produce 
large amounts of IDO (187). Production of the tryptophan-catabolizing enzyme IDO by pDCs is 
known to enhance Treg activation, such that Tregs isolated from tumor draining lymph nodes 
efficiently shut down CTL proliferation (188). Tumor cell necrosis results in release of many 
DAMPs including HSPs, self-DNA, and high motility group box 1 (HMGB1). Treatment of pDCs 
with DAMPs such as HMGB1 inhibits maturation and adhesion molecule expression, and inhibits 
Th1-skewing responses in CpG-stimulated pDCs (189). We hypothesize that a similar pathway is 
being induced in pDCs that bind gp96. 
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4.0  CHAPTER 2: GP96 DRIVES DICHOTOMOUS T CELL IMMUNE RESPONSES 
VIA DNA METHYLOME REMODELING IN APCS 
PREFACE 
Most of the data in this chapter has been published in Nature Communications, of which I am first 
author (79). Figures 12, 14, 15, 17-26, and 28, and Tables 5-8 are copyright (2017) Nature 
Publishing and is distributed under a Creative Commons CC-BY license. This information is 
presented here and expanded upon by the author. 
4.1 RATIONALE 
Given the findings that pDCs are actively targeted following HD gp96 immunization, it is possible 
that signaling and expression events are elicited in these DCs that are distinct from their cDC 
counterparts. The fact that pDCs do not undergo maturation in response to gp96 stimulation 
suggests that either 1) pDCs utilize a different HSP receptor, resulting in differential activation of 
downstream signaling events, or 2) pDCs activate a genetic profile that is distinct from cDCs. 
Similar to cDCs, pDCs bind gp96 in a CD91-dependent manner, such that addition of CD91 
neutralizing antibodies or CD91 ligand α2M to the culture medium abrogates binding of labeled 
gp96 (1). Observation of gp96-treated pDCs by microscopy also revealed that NF-κB is 
translocated to the nucleus following gp96 stimulation. Therefore, it is unlikely that an ancillary 
receptor and/or signaling pathway is promoted by gp96 binding in pDCs. I instead propose that 
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HSP-CD91 binding activates distinct gene signatures in pDCs that are absent in cDCs, and that 
this signature is a product of epigenetic regulation. 
For many years, DNA methylation was regarded as a stable and often permanent epigenetic 
mark that invariably leads to gene silencing. Consequently, its role in controlling transcription and 
driving immune cellular responses has been neglected. Emerging studies show that in T cells and 
APCs, active modification of the methylome may occur in response to external stimuli, controlling 
IL-2 production and proteome modifications in response to pathogens. Interestingly, NF-κB can 
reportedly interact with DNMT1 and guide it to target genes (121). In this study, both NF-κB and 
DNMT1 were required for full methylation and repression of target gene BRMS1. Breast cancer 
metastasis suppressor 1 (BRMS1) is a tumor metastasis suppressor that is downregulated in many 
cancers, thus understanding the mechanisms through which its expression is repressed is critical. 
Because NF-κB is intricately involved in APC responses to gp96 and other immunogenic HSPs, 
it is possible that it plays a role in modifying the epigenetic landscape of HSP-responsive cells. 
Secreted hsp90 can bind prostate cancer cells and promote expression of the methyltransferase 
enhancer of Zeste homolog 2 (EZH2), a catalytic component of the Polycomb complex 2 
(PRC2)(190). Binding of hsp90 induced ERK signaling, which in turn stabilized PRC2 and 
enhanced recruitment of EZH2 to the E-cadherin promoter. This work is among the first to show 
that signaling events initiated by HSPs have the potential to drive downstream epigenetic events. 
In this section, I present data to support that gp96 influences activation of epigenetic 
machinery to regulate the DNA methylome of responding cells. In particular, dynamic changes to 
the methylation status of genes involved in cell-cell adhesion, signaling, and angiogenesis occur 
following gp96 immunization. Through these assays I have identified Nrp1, an adhesion molecule 
expressed by pDCs and Treg, as a promising candidate for driving the HD gp96 response. 
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4.2 RESULTS 
4.2.1 Gp96 treatment leads to formation of DNMT1 punctae in APCs 
DNA methylation is catalyzed by the enzymes DNMT1, DNMT3a, and DNMT3b. We tested 
whether cDCs and pDCs cultured in the presence of gp96 modify nuclear organization of DNMTs 
by confocal microscopy. Splenic pDCs and a range of cDCs including BMDCs, primary isolated 
splenic CD11c+ DCs, and PECs, were separately cultured in the presence of gp96 for 6 hr on glass 
coverslips. The cells were then probed by immunocytochemistry for formation of punctate DNMT 
structures within the nucleus, an established indicator of binding of DNMT to target genes (162). 
Using the analysis tools described in Methods, the average number of DNMT punctae per cell was 
calculated. We observed a significant and similar increase in DNMT1 punctae in gp96-stimulated 
cDCs and pDCs after 6 hr (Figure 9A,B,C) compared to the diffuse with little to no punctae in 
PBS-treated cells. Conversely, DNMT3b punctae was detected only in PECs (Figure 10). Thus, 
DNMT1 is universally activated in response to gp96, whereas DNMT3b may only be activated in 
select cell populations. This is consistent with previous reports which show that DNMT1 and 
DNMT3b can form complexes independent of DNMT3a (191). Gp96-mediated DNMT1 punctate 
enrichment was accompanied by elevated, but not significantly increased, DNMT1 protein in 
nuclear extracts purified from BMDCs (Figure 11A,B). Therefore, changes to DNMT1 nuclear 
architecture, rather than overall increased DNMT1 expression, were initiated by gp96 in 
responding cells. DNMT1 punctae formation was not a result of proliferation as treated cells did 
not significantly proliferate throughout the duration of the experiment and lacked co-localization 
of DNMT with Ki67 (Figure 11C,D) which is expressed at the S-phase during cell proliferation 
and DNA replication.  
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Figure 9. DNMT1 forms punctae in DC nuclei following gp96 stimulation. 
A. Indicated DCs were stimulated with gp96 or treated with PBS in vitro on coverslips for 6 hr. Cells were stained 
and analyzed by confocal microscopy. B. DNMT1 punctae were quantified using NIS Elements software and in-house 
algorithms as described in Methods. Each point represents the average punctae per cell from one field of view. Data 
are from 1 representative experiment of 3 independent experiments.  
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Figure 10. DNMT3b forms punctae in macrophage nuclei following gp96 
stimulation. 
PECs were stimulated with gp96 or treated with PBS in vitro on coverslips for 6 
hr. Cells were stained and analyzed by confocal microscopy. 
PBS 
gp96 
 
membrane 
DAPI 
DNMT3b 
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Figure 11. DNMT1 punctae are not an artifact of increased protein or cell proliferation. 
A-B. Nuclear extracts from cDCs after 18 hr gp96 stimulation were harvested for western blot analysis. Lamin B1 
was used as a loading control. Data are from 1 representative experiment of 3 independent experiments. C-D. BMDCs 
were treated with gp96 for 6 hr then stained for Ki67 and observed by confocal microscopy. CTCF was calculated in 
Image J using the calculation: Integrated Density – (Area of selected cell  X Mean fluorescence of background 
readings) 
4.2.2 DNMT1 punctae formation is NF-κB dependent 
We next sought to determine the signaling mechanism(s) responsible for this DNMT activity. It 
has been shown in tumor cells that DNMT1 can complex with the phosphorylated p65 subunit of 
NF-κB (121). Because NF-κB is critical for the gp96 response in all APC types that have been 
tested, we hypothesized that this is a mechanism utilized by gp96. PECs were given gp96 in vitro 
in the presence or absence of NF-κB inhibitor cardamonin. This inhibitor prevents degradation of 
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IκBα and thus prevents its activation and nuclear translocation. We treated PECs with 10 µM 
cardamonin, consistent without previously published studies on NF-κB activation in HSP-treated 
PECs and RAW macrophages (62). DMSO-treated cells were included as a control. After 6 hr 
incubation, cells were stained and observed by microscopy for changes in DNMT architecture. 
Addition of cardamonin to the media was sufficient to prevent DNMT1 punctae (Figure 12A,B). 
Thus, NF-κB seems to play a role in DNMT activation, similar to previously published findings. 
 
Figure 12. DNMT1 punctae formation in gp96-stimulated macrophagess is 
NF-κB dependent. 
A-B. PECs were treated with HD gp96, in the presence of 10 µM NF-κB inhibitor 
cardamonin (DMSO as negative control). DNMT1 punctae analysis was performed 
by confocal microscopy after 6 hr. CM, cardamonin. 
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Figure 13. Gp96 treatment does not result in phosphorylation of GSK3β. 
BMDCs (A-B) or pDCs (C-D) were treated with 200 ug/ml gp96. After 15 min, 
cell lysates were harvested for western blot analysis. 
 
Another signaling pathway involved in DNMT1 activation and expression is via 
phosphorylation of GSK3β (192). Inhibition of GSK3β, which occurs via phosphorylation, is 
associated with stabilization of DNMT by preventing its degradation. This phenomenon has been 
observed in both T cells and cancer cells (162, 192). CD91 is known to control GSK3 signaling to 
regulate lipolysis (77) and response to apolipoprotein E (193, 194), but whether this pathway is  
utilized downstream of HSP-CD91 interaction has not been reported. We tested whether  
phosphorylation of GSK3β occurs in cDCs and pDCs stimulated with gp96. All samples were 
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gp96 compared to PBS controls in either cell type (Figure 13A-D), suggesting that this pathway is 
not involved in gp96 responses or gp96-mediated regulation of DNMT.  
4.2.3 DNA methylome remodeling occurs in CD91+ cells in response to gp96 
immunization 
DNA methylation is a critical modification responsible for transcriptional regulation of cytokines, 
growth factors, molecules involved in synapse formation and other aspects of immunologic 
responses. Given that APCs activate DNMTs via an NF-κB dependent pathway (Figure 12), we 
hypothesized that APCs undergo methylome remodeling in response to gp96 immunization. We 
examined DNA methylation first in total CD91+ cells following immunization of mice with LD or 
HD gp96 to determine if changes in methylation was a mechanism for controlling the divergent T 
cell immune response. A whole genome methyl-seq approach was taken using MBD protein-based 
purification of methylated DNA. Mice were immunized with LD or HD gp96 or given PBS. 
Eighteen hr post-immunization, mice were sacrificed and CD91+ cells were isolated by FACS from 
draining lymph nodes. The target cell population and time point were chosen in accordance with 
the outcomes in Figure 4 and previously published results (61). We generated 36-55 million 
filtered and aligned single-end reads per sample. Methylated DNA was sequenced to ~11-fold 
coverage and analyzed for differential methylation. In this manuscript, intergenic regions are 
defined as any sequence >2,000 bp distal from annotated genes including alternate promoter and 
cis-acting regulatory sequences. Intragenic regions include sequences <2,000 bp up or downstream 
from an annotated gene or within the gene body.  Consistent with previous reports, the majority of 
detected differentially methylated regions (DMRs) occurred in intergenic regions, and those which 
occurred in intragenic regions were largely located within introns (Figure 14A,B). Only a small 
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percentage of DMRs were detected on promoter regions. Methylation was largely not present at 
transcription start sites (TSS) and CpG islands (Figure 14C), although methylation signal did 
increase immediately flanking these sites. This patterning is consistent with what others have 
reported for DNA methylation sequencing (153).  
From this dataset, 184 intergenic and 55 intragenic DMRs were identified exhibiting 
variance between LD and HD gp96 immunized cohorts (Tables 5 and 6). Of the 55 intragenic 
DMRs, 29 were hypermethylated in HD and 26 were hypermethylated in LD. Methylation scores 
for all detected peaks were plotted, with DMRs highlighted to show divergence between samples 
(Figure 14D). Using parameters described in Methods, Gene Ontology (GO) analysis was 
performed on intragenic DMR genes and showed that the bulk of intragenic DMRs occur within 
pathways which primarily regulate cell-cell contact and adhesion, intracellular signaling and 
angiogenesis (Figure 15A; Table 7,8). A representative list of genes, most of which are expressed 
by APCs (Tables 7 and 8), enriched for cell-cell interaction are shown (Figure 15B).  
4.2.4 Increase in Nrp1+ pDCs following HD gp96 immunization 
We then focused on differential methylation and expression of target adhesion molecules in CD91-
expressing APCs since APC-T cell contact is critical for proper T cell activation. One of the 
identified adhesion molecules, Nrp1, known to control Treg responses when expressed in pDCs, 
was notable. Nrp1 has the most well-established role in controlling DC-Treg interaction at steady 
state and regulating Treg activation in the tumor microenvironment (195-197).  Nrp1 showed 
intragenic methylation in samples from HD gp96 immunized mice but not from LD immunized 
mice (Figure 15B). To determine the effect of gene methylation on Nrp1 protein expression, mice 
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were immunized with gp96 and 18 hr later draining lymph nodes were stained for markers of cDCs 
and pDCs and analyzed for Nrp1 expression by flow cytometry. The percentage of Nrp1+ pDCs 
was significantly increased when mice were immunized with HD but not LD gp96 (Figure 16A). 
Interestingly, cDCs showed no increase in Nrp1 expression following gp96 immunization at either 
dose. No changes in Nrp1 expression were detected in B cells, T cells, NK cells and other CD11c+ DCs 
(Figure 16B) at any dose of gp96 tested. 
 
Figure 14. Differential methylation of adhesion molecules in response to gp96. 
Mice were immunized with LD or HD gp96 or treated with PBS. DNA was purified from isolated CD91
+
 lymph node 
cells, fragmented and methylated sequences were enriched using methyl-binding domain protein (MBD). Methylated 
DNA was sequenced. A. Pie chart shows distribution of total DMRs on intergenic versus intragenic regions. Here, 
intergenic is defined as any sequence >2000 bp away from any annotated gene, and intragenic is defined as any 
sequence within 2000 bp of an annotated gene. B. Intragenic DMRs were analyzed for distribution on gene elements 
(promoters, introns, and exons). C. Average signal profile for methylation enrichment across transcription start sites 
(TSS) and CpG islands. D. Scatter plot of coverage scores for all methylated genes in LD and HD samples. Any genes 
defined as DMRs are highlighted. 
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Table 5. List of methyl-seq DMRs (HD>LD, 29 targets) 
 
 
 
 
 
APC expression was determined using publicly available RNA seq data from The Immunological Genome 
Project (Immgen). Coverage for LD and HD samples is reflective of the average number of peaks found at 
that location and was calculated using BEDtools. Abbreviations: chr, chromosome; cov, coverage; cDC, 
conventional DC; pDC, plasmacytoid DC; LC, Langerhans cell; mo, monocyte; mac, macrophage 
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Table 6. List of methyl-seq DMRs (LD>HD, 26 targets) 
 
 
 
 
 
 
 
APC expression was determined using publicly available RNA seq data from The Immunological Genome Project 
(Immgen). Coverage for LD and HD samples is reflective of the average number of peaks found at that location 
and was calculated using BEDtools. Abbreviations: chr, chromosome; cov, coverage; cDC, conventional DC; 
pDC, plasmacytoid DC; LC, Langerhans cell; mo, monocyte; mac, macrophage 
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Table 7. List of GO analysis hits (HD>LD) 
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Table 8. List of GO analysis hits (LD>HD) 
 
 
Figure 15. DMRs are enriched on genes associated with adhesion. 
A. Gene Ontology analysis of all DMRs identified in LD and HD. Adh = adhesion; Sig = signaling; Ang = 
angiogenesis. B. Sample genes within the adhesion gene family set, with log(coverage) shown. 
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Figure 16. pDCs specifically increase expression of Nrp1 in reponse to HD gp96. 
A. Mice were immunized with LD or HD gp96 and draining lymph nodes were harvested and stained with markers 
for pDC or cDC plus Nrp1. Cells were analyzed by flow cytometry for changes in percentage of Nrp1
+
 in respective 
pDC and cDC gates. One set of representative flow plots is shown. B. Lymph nodes were harvested after 18 hours 
and stained for NK cells (NK1.1), CD4
+
 T cells (CD3, CD4), Treg (CD3, CD4, Foxp3), and DC subsets (CD11b, 
CD11c, CD8, CD205). n=5, data are from 1 representative experiment of 3 independent experiments. Bar graphs on 
the right are the average percentages from multiple experiments  
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Figure 17. pDCs recapitulate in vivo HD phenotype in an in vitro culture system. 
A,B. Splenic pDCs were isolated, treated with LD or HD gp96 ex vivo, and Nrp1 expression 
was measured by flow cytometry. C. Splenic pDCs were isolated, treated with LD or HD 
gp96 ex vivo, and Nrp1 expression was measured by qPCR. In B and C, data are pooled 
from 3 independent experiments.  
4.2.5 Gp96-mediated Nrp1 gene methlyation regulates Nrp1 gene product expression in 
pDCs, but not cDCs 
We established an in vitro system to examine the specific effect(s) of gp96 on pDCs observed in 
HD immunized mice. We chose our in vitro based on: 1) estimates of internal volume following 
i.d. injection, 2) number of cells exposed to injected gp96 at the injection site and draining lymph 
node, 3) historic data using gp96-treated DCs in vitro, 4) the amount of gp96 per tumor cell 
resulting in release of gp96 in vivo and 4) a dose titration which copied the phenotypes we observe 
with in vivo immunization. We used 200 µg/ml and 10 µg/ml gp96 in culture to represent HD and 
LD gp96 in vivo respectively. Nrp1 expression on the surface of pDCs was examined by flow 
cytometry following treatment of cells in culture with HD or LD. The percent of Nrp1+ pDCs is 
enhanced when cells were treated with HD gp96 but not LD gp96 or PBS, recapitulating the effects  
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Figure 18. Intronic methylation of Nrp1 enhances expression. 
A. Schematic of methylation within Nrp1 at intron 2 from whole genome methyl seq data. Splenic pDCs were isolated 
from naïve mice and stimulated with HD gp96. Purified DNA was analyzed by clonal bisulfite sequencing. Each line 
of bisulfite seq data represents one treatment group. Filled portions pie-charts signify methylated samples; open slices 
signify unmethylated samples. Only differentially methylated cytosines are shown; both CpG and non-CpG are 
included. B-C. Percent of methylated cytosines of total cytosines as measured by clonal bisulfite sequences is shown 
for pDCs (B) and BMDCs (C). Data are from 1 representative experiment of 2 independent experiments D. Schema 
of experiment. Mice were treated with 5 mg/kg 5-aza and 48 hr later pDCs were isolated for gp96 treatment. E. Splenic 
pDCs were stimulated with HD gp96 ex vivo for 18 hr. Cells were stained for pDC markers and Nrp1, and analyzed 
by flow cytometry. Percent of Nrp1
+
 pDCs of total pDCs is shown F. Proposed model of methylation of NRSF binding 
site in Nrp1 gene body. 
 
seen in vivo (Figure 17A,B). Nrp1 mRNA levels were also measured in pDCs treated with LD or 
HD gp96 by qPCR (Figure 17C). In agreement with protein expression, Nrp1 mRNA increased 
significantly when cells were treated with HD gp96 but not LD gp96. Following the consistent 
Nrp1 protein expression patterns in pDCs in vivo and in vitro we next confirmed the methyl-seq 
data in pDCs stimulated with HD gp96 in vitro. pDCs were cultured in the presence of HD gp96, 
and analyzed at a single base resolution of the Nrp1 intronic DMR by clonal bisulfite sequencing 
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(Figure 18A). Bisulfite-treated DNA was PCR amplified with specific primers. PCR amplicons 
were cloned and sequenced and are indicated as circles which represent individual cytosines 
differentially methylated in either sample (Figure 18A). Consistent with the methyl-seq dataset 
(Figure 15B), the percentage of total methylated cytosines within intron 2 of Nrp1 was 
significantly increased in gp96-treated pDCs versus untreated pDCs (Figure 18B). cDCs 
(represented by BMDCs) did not exhibit this change in methylation of Nrp1 (Figure 18C). These 
data are also consistent with previous observations, in that methylation within such non-promoter 
regions was associated with enhanced protein expression (198-200). The effect of DNA 
methylation initiated at the Nrp1 locus on protein expression is reflected in the increase in protein 
expression (Figure 16A, 17). We next verified that DNA methylation was responsible for increased 
Nrp1 expression by inhibiting DNA methylation. Mice were administered 5-azaC, a potent 
inhibitor of DNMTs, 72 hr prior to isolation of pDCs. pDCs from 5-azaC treated or untreated mice 
were incubated in vitro with HD gp96 and analyzed for Nrp1 expression by flow cytometry (Figure 
18D). 5-azaC completely blocked the upregulation of Nrp1 in pDCs treated with gp96 in vitro 
(Figure 18E).   
To understand the disparity in methylation patterns at the Nrp1 locus and Nrp1 expression 
in pDCs and cDCs, we examined chromatin accessibility in naïve cells (Figure 19). Chromatin 
was extracted from cDCs or pDCs and digested with nuclease. The Nrp1 locus was then amplified 
and quantified with specific primers by qPCR. In this chromatin accessibility assay, when the DNA 
is in a heterochromatin (closed) state, it is inaccessible to nuclease digestion and will result in 
insignificant CT shifts between digested and undigested samples (Figure 19A). DNA in a 
euchromatin (open) state will be susceptible to nuclease digestion and result in large CT shifts 
upon amplification. We observed that at a basal state, Nrp1 in pDCs is in an open confirmation 
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and thus more accessible, as revealed by the large fold enrichment score (Figure 19B). In contrast, 
Nrp1 was in a closed chromatin state in cDCs. These data indicate that pDCs are more poised for 
regulation of Nrp1 at a genetic level (Figure 19C). 
 
Figure 19. Nrp1 is in an euchromatin conformation, and thus poised for regulation, in naïve pDCs but not 
cDCs. 
A. Schematic of chromatin accessibility experiment. B. Chromatin was purified splenic pDCs or cDCs isolated from 
naïve mice and digested. Chromatin accessibility at the Nrp1 region of interest was assessed by qPCR. Fold 
enrichment was calculated using the formula: FE = 2^(NseCT-noNseCT) x 100%. n=3/group, data are pooled from 3 
independent experiments. C. Nrp1 in pDCs is open and thus more accessible for regulatory factors including DNMT, 
NF-κB, and STAT5a. 
4.2.6 Gp96-stimulated pDCs stabilize and prolong interactions with Treg in a Nrp1-
dependent manner 
Nrp1 expression by pDCs facilitates long-term homotypic Nrp1-Nrp1 or heterotypic Nrp1-Sema4a 
interaction with Treg cells (195, 197). Having established that both HD gp96 immunization and in 
vitro gp96 stimulation result increased Nrp1+ pDCs, we investigated whether in vitro gp96-
stimulated pDCs prolonged interaction with Tregs as measured by time-lapse live cell microscopy. 
pDCs and Tregs were isolated from spleens. pDCs were cultured for 18 hr with HD gp96, and for 
the last 2 hr in the presence or absence of Nrp1 blocking or isotype control antibody. CellTracker 
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Red-labeled CD4+CD25+ Tregs were added to the culture and imaged for 2 hr, with frames taken 
at 5 min intervals. Figure 20A shows representative pDC-Treg interactions over time. HD gp96 
significantly increased interaction time between pDCs and Tregs and this interaction could be 
blocked by α-Nrp1 antibodies but not by an isotype control antibody (Figure 20A,B,C). 
Interactions were considered “long” if the pDC-Treg interaction lasted >10 min. Any interaction 
that lasted <10min was deemed transient, and placed in the “little/no interaction” category. In all 
samples, some baseline level of long interaction was observed, which is in agreement with Tregs 
scanning for antigen and/or recognition of self-antigen to maintain the Treg lineage. However, 
Nrp1 antibody did not have an overall inhibitory effect on baseline long interactions. Over the 
course of the experiment the gp96-treated pDCs did not undergo maturation and maintained an 
immature phenotype (Figure 8B), further supporting previous findings that Nrp1-expressing 
immature DCs efficiently interact with Treg (195).  
Furthermore, we tested whether this phenomenon is Treg-specific, or if gp96-stimulated 
pDCs increase interaction with conventional T cells (Tconv), identified as CD4+CD25- isolates 
from the spleen. Tconv were co-cultured with pDCs treated in the same way as for the Treg in 
Figure 20B. There was no change in pDC-Tconv interaction regardless of gp96 or antibody 
treatment (Figure 20D,E), suggesting that this is a Treg-specific event and further supports the 
dependence of Nrp1 since Tconv do not express high levels of Nrp1.  
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Figure 20. gp96-stimulated pDCs increase interaction with Treg in a Nrp1-dependent manner. 
A-E. Splenic pDCs were plated on coverslips with or without HD gp96, and in the presence or absence of Nrp1 
blocking antibody (α-Nrp1) or isotype control antibody (Iso). Prior to imaging, Treg (CD4+CD25+) or Tconv 
(CD4+CD25-) were labeled with Cell Tracker Red dye and added to the pDC culture dishes at a 2:1 DC:T cell ratio. 
Images were acquired at 5 min intervals for a total of 2 hr. Interaction and motility were analyzed. B. Treg were 
tracked using NIS Elements tracking software. Representative Treg-pDC interactions are shown for each treatment 
group for the indicated times. The interaction times of Tregs with pDCs from multiple images are quantified. All Tregs 
(including those that failed to interact with pDC) are included. C. The average percentage of Tregs which undergo 
long (>10 min) or short to no (0-10 min) interactions with pDCs were calculated for each group. D,E. Tconv were 
analyzed similarly to Treg. Total interaction time (D) and percentage of long interaction (E) are shown. All data are 
from 1 representative experiment of 2-3 independent experiments.  
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Figure 21. Duration of pDC-Treg interaction increases 
with increasing treatment dose of gp96. 
pDCs were treated with LD or HD gp96 for 18 hr. As 
described in Methods, pDCs were also treated with α-Nrp1 
blocking antibody or isotype control and co-cultured with 
labeled Treg. The percentage of cells which had undergone 
long term interactions in each group was calculated and is 
shown. 
 
Although LD treatment of pDCs resulted in a marginal increase in pDC-Treg stabilization, 
it was significantly lower than stabilization achieved with HD (Figure 21). Stimulation of pDCs 
with gp96 therefore prepares these pDCs for longer interaction with Treg by increasing expression 
of Nrp1.  
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4.2.7 pDCs are required for gp96-mediated immune suppression by Tregs 
We have implicated CD91+CD11c+ cells in HD gp96-mediated suppression of tumor immunity 
(Figure 3) and shown that gp96-conditioned pDCs have the capacity to engage and form stable 
interactions with Tregs via Nrp1 (Figure 20). We next established a gp96-mediated suppression 
     
Figure 22. pDCs are required for efficient suppression of CTL-mediated cytotoxicity by HD gp96. 
A. Schema for experiment. Mice were immunized intraperitoneally (i.p.) with irradiated OVA-expressing cells to 
generate an anti-OVA response. On the same day, mice were depleted of pDCs via intraperitoneal injection of a-
PDCA depleting antibody. Mice were given a HD of gp96 24 hr later. In vivo cytotoxicity was measured 6 days later 
by flow cytometry. B. Percent cytotoxicity was calculated as described in Methods and is shown for each group. C. 
Shown are representative flow plots for CFSE-labeled SIINFEKL-pulsed target splenocytes (CFSE-high) and 
unpulsed non-target splenocytes (CFSE-low) for each treatment group. Data are pooled from 2 independent 
experiments.  
 
assay to test the role of pDCs in vivo (Figure 22A). Mice were immunized with irradiated, antigen 
(OVA)-expressing or non-expressing B16 tumor cells (Group 1 and 2 respectively). OVA-specific 
 74 
CTL activity was measured in vivo by intravenous injection of OVA peptide (SIINFEKL)-pulsed 
or unpulsed, differentially labeled target cells into mice. In this in vivo assay, CTL efficiently lysed 
SIINFEKL-pulsed target cells in mice immunized with B16-OVA (Group 2) but not with B16 
(Group 1) (Figure 22B,C). When mice were immunized with B16-OVA and treated with HD gp96 
one day later (Group 3), CTL activity was significantly abrogated (Figure 22B). This data is 
consistent with earlier observations of Treg generation by gp96 treatment. pDCs were depleted 
with specific antibody or control IgG in this assay as described in Methods. When pDCs were 
depleted (Group 4), HD gp96 treatment failed to abrogate CTL mediated lysis of target cells 
(Figure 22B). Control mice immunized with B16- OVA and depleted of pDCs in the absence of 
gp96 treatment (Group 5) still elicited CTL activity comparable to Group 2.  
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Figure 23. HD gp96-mediated Treg induction is Nrp1-dependent. 
A. Schema to determine Nrp1 requirement for HD gp96-mediated suppression. Mice were immunized i.p. 
with irradiated tumor cells. On day 7, mice were given HD gp96 (i.d.) and one intraperitoneal dose of α-Nrp1 
neutralizing antibody. On day 14, mice were sacrificed for analysis. Draining inguinal LNs (B,C) spleen (D,E) 
were harvested for flow cytometry analysis of CD4
+
Foxp3
+ 
Treg and total CD4 cells. Data are pooled from 2 
independent experiments. 
4.2.8 Nrp1 is essential for gp96-mediated Treg generation 
Using the HD gp96 assay previously established, we measured the increase in Treg populations as 
a function of HD gp96 administration (Figure 23A). Mice were immunized with irradiated B16-
OVA followed by treatment with HD gp96. Nrp-1 blocking antibody or isotype control antibody 
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was co-administered with HD gp96. The increase in Treg percentages in draining lymph nodes 
achieved with HD gp96 was absent when Nrp1 antibody was co-administered (Figure 23B). The 
total percentage of CD4 T cells however did not change (Figure 23C). This seems to be a local 
effect in the draining lymph node, since no change in Treg or CD4+ T cells was observed in the 
spleen with any treatment (Figure 23D,E). This is in agreement with previous findings in which 
gp96 is passively drained to the lymph nodes where T cell responses to gp96-bound peptides are 
likely generated (61). OVA-specific CTLs in the draining lymph nodes of immunized animals were 
measured to determine whether HD gp96 immunization can prevent CTL activation. We observed 
only a slight increase in tetramer-positive CTLs with B16-OVA immunization, and this number 
did not decrease with HD gp96 administration (Figure 24A,B), suggesting that the rise in Treg 
does not effect antigen-specific CTL generation in our system. It is possible that, although there is 
no difference in the number of tetramer positive CTLs that are induced, that these CTLs are less 
active compared to those induced in the absence of HD gp96 immunization. The ability of these 
CTLs to lyse OVA+ tumor cells should be assessed in the future to test this possibility. Together 
these data identify pDCs as a key APC controlling HD gp96-mediated suppression of protective 
immunity and that Nrp1 is instrumental in these observations, via increased methylation and 
expression. Further experimentation is needed in order to understand the outcome of Nrp1-Nrp1 
ligation in terms of its effects on Treg, including survival and expression of suppressive mediators 
such as IL-10.  
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Figure 24. HD gp96 immunization does not affect generation of antigen-specific CTLs. 
A. Experimental schema. Mice were immunized i.p. with OVA-expressing irradiated B16 
tumor cells or WT B16. On day 7, mice were given HD gp96 (i.d.) and one intraperitoneal 
dose of α-Nrp1 neutralizing antibody. On day 14, mice were sacrificed for analysis. B. 
Draining inguinal LNs were harvested for flow cytometry analysis of CD8
+
 and OVA 
tetramer
+
 CTLs.  
4.3 DISCUSSION 
Our studies have revealed, for the first time, a DC phenotype associated with a suppressive 
response to gp96 which can be recapitulated in vitro. Although CD91 is required for gp96-
mediated immune responses, the engagement of CD91 by gp96 can occur on multiple APC types, 
ultimately determining the type of dominant immune response. We propose that this occurs via 
DNA methylome remodeling in DC, leading to altered expression of various adhesion molecules 
(Figure 25). The importance of DNA methylation in driving expression of genes involved in 
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immunity has recently begun to emerge. In our study, we assessed methylome changes in CD91+ 
cells isolated from immunized mice. Although the vast majority of CD91+ cells are DCs and 
macrophages, this does not represent a pure population of target cells and must be taken into 
account in interpreting the results of our methyl-seq dataset. However, our present study was 
focused on Nrp1, and we have identified the specific DC subset involved and have validated these 
data using bisulfite sequencing and flow cytometry in these DCs. Additional target genes identified 
in our screen and expressed in these particular subsets or others will need to be further investigated 
for their possible contributions in modulating the magnitude and nature of gp96-mediated immune 
responses, keeping in mind that DC-Treg interactions are mediated by a myriad of adhesion 
molecules. Once we identify the full complement of adhesion molecules, we can address the issue 
of Nrp1 sufficiency in the pDC-Treg interaction.  
4.3.1 Activation of DNMTs, transient methylation, and non-promoter methylation 
We have focused on DNA methylation here because of its emerging role in immune regulation. It 
has recently been shown that NF-κB can directly associate with DNMT1 in tumor cells, effectively 
guiding DNMT1 to certain target genes (121). The role of NF-κB signaling in response to 
immunogenic HSPs has been well documented by our lab and others, and is a known potentiator 
of gp96 responses in both cDCs and pDCs (1, 62, 70). It is possible that NF-κB signaling 
downstream of CD91 is the catalyst for the methylome remodeling that we have observed. 
Although DNMT1 is primarily responsible for maintenance methylation, it can also cooperate with 
DNMT3 to initiate de novo methylation (151). In peritoneal macrophages, we observed both 
DNMT1 and DNMT3b punctae in response to gp96 stimulation, suggesting that both may be 
specifically recruited to chromatin. The accessibility of DNMT target sites to the enzyme provides 
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physical constraints on whether genes and/or regulatory elements are methylated and therefore can 
determine changes in expression. We observed that a regulatory element within Nrp1 is in a closed 
chromatin formation (thus inaccessible) in naive cDCs but open in naive pDCs (Figure 19). This 
offers an explanation for the observed methylation patterns when stimulated with gp96, despite 
the similar activation patterns of DNMT1 in both cell types. Other epigenetic machinery which 
may be activated in response to gp96 including histone modifying microRNAs and enzymes are 
currently being examined in our model systems. 
 
Figure 25. Chapter 2 summary. 
At low doses, gp96 engages cDCs. Following epigenetic changes and cross-
presentation of chaperoned peptides, cDCs elicits Th1 anti-tumor immunity, 
characterized by enhanced CTL and NK cell function. At high doses gp96 
engages a significantly greater percentage of pDCs. Following epigenetic 
remodeling, distinct from that in cDCs, pDCs stabilize interactions with 
Tregs via Nrp1 that suppresses ongoing Th1 responses in tumors. 
x 
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4.3.2 Methylation of cell-cell adhesion genes: lessons from neurobiology 
The majority of the DMRs that we detected in this study are associated with genes involved in 
cell-cell contact and adhesion. Interestingly, DNA methylation is known to play a critical role in 
mediating cell-cell contact and synapse formation within the nervous system (201, 202). Transient 
DNA methylation in postmitotic neurons is catalyzed by both DNMT1 and DNMT3a (203, 204). 
There have been several reports that neuronal activity leads to modification of histones and the 
DNA methylome in adult brains (201, 202). Gene ontology (GO) analysis of differentially 
methylated genes showed enrichment of genes associated with synaptic function in mouse 
hippocampi treated by electroconvulsive stimulation. Yet little is known about how DNA 
methylation regulates contact between immune cell populations. 
              
Figure 26. Potential NRSF binding motif identified in Nrp1 locus by MatInspector/Genomatix. 
 
Intragenic methylation of Nrp1 has been observed in human monocytes, but the 
consequences of this alteration on protein expression and function were not evaluated (205). 
Contrary to promoter methylation, which is typically associated with decreased gene expression, 
methylation within the gene coding sequence (intragenic) is often a mark of active expression 
consistent with our observations for Nrp1 in pDCs stimulated with gp96 (198). We performed 
x 
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transcription factor binding analysis on the Nrp1 DMR using Genomatix software and detected a 
possible binding site for NRSF/REST (Figure 26). This factor is a known repressor of Nrp1 
transcription in neurons and is highly expressed in non-neuronal cells including immune cells 
(206). It is possible that methylation at this site blocks the binding of the repressor and allows for 
increased Nrp1 transcription, although this remains to be formally tested. It is interesting that the 
basal level of chromatin accessibility of Nrp1 is different in naïve APC subsets. Whether gp96 
treatment can alter accessibility at this region in pDCs and cDCs has not been tested, however we 
hypothesize that it would remain open in pDCs following binding of gp96 (particularly at HD), 
since transcription is increased in this situation. Gp96 treatment of cDCs would presumably have 
no effect on accessibility, as evidenced by the lack of Nrp1 transcription in these cells. 
In addition to Nrp1, other genes which regulate cell adhesion were differentially 
methylated in our dataset. Although Nrp1 is most well-published in terms of APC-T cell 
interaction, it is entirely possible that other adhesion molecules are playing a role in the response 
to gp96. Several of the genes we identified are expressed by DCs and macrophages, including 
neuroligins, cadherins, and NCAM. Although the functional relevance of neuroligin on APCs is 
unknown, many molecules thought to be exclusively found on neurons have recently been 
appreciated in the context of immunity. For instance, targeting of neurokinin-1 receptor on DCs 
and Langherhans cells leads to increased cell survival, migration to lymph nodes, and IL-12 
production (207-209). Cadherins can have diverse impacts on the activity of immune cells; for 
instance, homophilic E-cadherin interactions can result in prolonged APC-T cell engagement, 
whereas binding of E-cadherin on the APC to KLRG1 on T cells results in disruption of cellular 
interaction and release of anti-inflammatory cytokines by the APC (210). The significance of these 
additional adhesion molecules on the gp96 response is currently under investigation. 
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4.3.3 Regulation of pDC-Treg interaction 
pDCs can elicit regulatory immune responses using a variety of mechanisms, including increased 
expression of IDO or upregulation of molecules associated with Treg stabilization and activation 
such as CTLA-4 and Nrp1 (195, 211).  Nrp1 expression by immature DCs and pDCs facilitates 
long-term interaction with Treg via homotypic Nrp1-Nrp1 interaction (195, 196). The role of the 
Nrp1-Sema4a signaling axis in maintaining Treg populations via expression of Bcl-2 and other 
survival factors within the tumor microenvironment has been documented (197). Whether 
intercellular Nrp1-Nrp1 interactions trigger similar signaling in Treg is not known but is under 
active investigation. In agreement with previous reports, we did not observe any increase in 
maturation in gp96-stimulated pDCs (Figure 8B). These DC do, however, maintain moderate-high 
levels of MHC II expression, which is critical for effective Nrp1-Nrp1 interaction with CD4+ Treg. 
It is interesting that we observe Nrp1 dependence with HD gp96 immunization, given that pDCs 
are more likely to prime natural Treg (nTreg) in the lymph nodes of mice (212). In the context of 
solid organ transplant, this phenomenon is associated with increased graft survival due to Treg 
expansion. nTreg are distinguished from induced Treg (iTreg) in that they are educated in the 
thymus rather than at peripheral sites, show more stable expression of Foxp3 through complete 
demethylation of the Foxp3 promoter, and high expression of Nrp1 (213). Whether the preference 
of pDCs for nTreg is due to Nrp1 expression on both cell types was not tested. Additionally, it has 
been shown that immunization with a fragment of hsp70, called B29, results in increased 
expression of Nrp1 on Treg (214). Nrp1 expression is not upregulated on Treg following 
immunization with fully intact HSP in this study or ours. It is possible that administration of 
specific fragments of immunogenic HSPs can improve regulatory immunity by enhancing Nrp1 
on both pDCs and Treg. 
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Although the circumstances in which antigen presentation occurs on pDCs is contested, it 
has been reported that the triggering of various endocytic receptors on pDCs results in the 
increased capacity of these cells to present antigen (215). Endocytosis of gp96-CD91 complexes 
on pDCs could allow for presentation of self antigen(s) chaperoned by gp96. We observed that 
HD gp96-mediated suppression is dependent on pDCs, since their depletion results in maintenance 
of CTL lysis of target cells (Figure 22). It is possible that higher doses of gp96 are required to 
diffuse to pDCs, which normally reside within the T cell zone or pDCs are less sensitive to gp96 
and require a higher dose for activation. In addition to Treg activation, gp96 stimulated pDCs may 
also play a role in limiting cDC activation (1). Previous work from our lab has shown that, at least 
in vitro, gp96-stimulated pDCs abrogates the ability of cDCs to mediate pro-inflammatory 
responses.  Considering that both DC types interact with gp96 after HD immunization, pDCs offer 
a two-pronged approach to inhibition of Th1 responses. 
Our studies provide a better understanding of how dichotomous immune responses may be 
initiated and regulated based on the nature and dose of an administered immunogen. Following 
demonstrable efficacy in mouse models of cancer, LD gp96 is currently in clinical trials for the 
immunotherapy of cancer. HD gp96 therapy of autoimmune disease has only been documented in 
mice, but clinical trials are anticipated in the future. Although the specific amount of gp96 required 
for LD immunity in cancer trials has been calculated, it is unknown precisely how much gp96 is 
required to elicit the HD response in humans. Moreover, it is entirely possible that a successful 
dose in one patient will be unsuccessful in another, possibly due to the number of pDCs present in 
lymph nodes at the time of immunization and other immunosuppressive factors that are present 
within the tumor microenvironment. Although there are no known biomarkers to predict gp96 
immunization success, results from this study suggest that a high number of Nrp1+ pDCs may be 
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detrimental for cancer immunotherapy, but beneficial in the context of autoimmunity. More studies 
are needed to test how we can increase pDC-mediated uptake of gp96 and how this may improve 
autoimmunity.  
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5.0  CHAPTER 3: STAT1 SIGNALING IN GP96-STIMULATED APCS 
PREFACE 
The data in this chapter has been generated for a manuscript co-authored with Abigail Sedlacek, a 
postdoctoral researcher in the lab. Some of the data presented has been generated by Dr. Sedlacek, 
and is included with her permission (indicated with ALS in the figure legend). Figures 34B and 
36A,B are copyright (2016) Nature Publishing and is distributed under a Creative Commons CC-
BY license (30). All other figures are unpublished work. 
5.1 RATIONALE 
In addition to acting as the endocytic receptor for HSP-peptide complexes, CD91 is also known to 
act as a signaling receptor. In response to all immunogenic HSPs that have been tested, it is known 
that: 1) the intracellular tail of CD91 contains two NPXY motifs that become phosphorylated upon 
ligand binding, 2) NF-κB is activated and translocated to the nucleus, and 3) p38 MAPK is 
phosphorylated (62). NF-κB is essential for the increased expression of maturation and 
costimulatory markers on the surface of APCs and is responsible for secretion of various cytokines. 
The role of p38 MAPK activation in gp96-treated APCs has not, to our knowledge, been fully 
tested. It can be inferred that MAPK may play a role in skewing of Th1 responses, as it is a known 
regulator of IL-12 production in APCs (216). As discussed in the Background section of this thesis, 
activation of p38 is associated with increased pSTAT1 levels, particularly on the serine site S727. 
It is therefore possible that HSP-CD91 binding can activate STAT1 through a p38-dependent 
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pathway (Figure 27). In addition to binding consensus sequences in target promoters, STAT1 can 
also enhance NF-κB signaling under certain contexts (97). Many STAT1-regulated cytokines 
including those of the CXCL family can enhance NK cell activation and recruitment, and in some 
cases can enhance cross-talk between NK cells and APCs (217, 218). We and others have 
previously established a potential role for NK cells in the gp96-mediated response (30, 217-219). 
Whether CXCL chemokines direct this cross-talk event in the context of gp96 treatment remains 
unknown. 
          
Figure 27. Activated p38 MAPK indirectly phosphorylates STAT1 at S727 site. 
p38 is known to direct STAT1 phosphorylation in response to IFN and integrin 
signaling. CD91 is known to activate p38 in response to HSPs. We propose that this 
event drives STAT1 signaling. IFN = interferon, Jak2 = Janus kinase 2, STAT1 = signal 
transducer and activator of transcription 1, CnB = calcineurin B subunit, αMβ2 = αMβ2 
integrin. 
 
NK cells play an important helper role in response to gp96 immunization, specifically in 
response to tumor-derived gp96 (30). Within this context, NK cells increase T cell-mediated lysis 
of tumor cells via IFNγ production. We also know that APCs are important facilitators of this 
activity and that they secrete cytokines known to enhance NK cell activation. Of the STAT1-
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dependent cytokines that are released in response to gp96, we have become particularly interested 
in CXCL10 due to its involvement in NK cell activation (217). In this Chapter, I present data to 
show that STAT1 is phosphorylated at its S727 site in APCs treated with gp96. This event requires 
intact CD91 and p38 MAPK. Subsequently, STAT1 binds to a putative binding site on the Cxcl10 
promoter. This event may be methylation-dependent, but requires further experimentation. Lastly, 
we show that APC-NK cell cross-talk in response to gp96 occurs through a CXCR3 driven 
pathway. This work will provide additional prospective methods to strengthen HSP-mediated anti-
tumor immunotherapy by targeting NK cells. 
5.2 RESULTS 
5.2.1 DNA methylation is enriched at transcription factor binding sites 
  
Figure 28. DNA methylation is enriched at transcription factor binding sites. 
Mice were treated as in Figure 14 and methylated DNA was sequenced. MEME-CHIP analysis of whole genome 
methyl-seq dataset is shown. The identified binding motifs and associated transcription factors are shown for the 
most significant motifs. Binding motifs containing methylated sequences in both low and high dose immunized 
mice are included. TF, transcription factor. 
x 
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Methylated DNA from CD91+ cells isolated from LD or HD gp96 immunized mice was sequenced 
as described in Section 3.2.3 and Methods. This dataset was analyzed using MEME-CHIP 
software. MEME-CHIP performs comprehensive motif analysis to detect transcription factor 
binding sites (TFBS) in large sets of sequences. Using the parameters specified in Methods, we 
detected motifs associated with both LD and HD gp96 samples and have presented a select list 
including the detected motif, the predicted transcription factor, and p value (Figure 28). Predicted 
TFBS methylated only in LD included Tgif2 (repression of TGF-β target genes), GATA3 (Th2 
responses), and Irf3 (IFN-γ response). Unique TFBS methylated in HD included Mzf1 (myeloid 
cell development), Zeb1 (inhibition of IL-2 expression), and Tcf7 (T cell survival). Intriguingly, 
STAT1, NFATC2 (T cell activation), and Rxra (retinoid receptor) binding sites were detected in 
both samples.   
Whether methylation at binding sites contributes to actual binding of the transcription 
factor is controversial (220). If there is an effect at all, it is often thought that methylation at a 
binding site is detrimental to transcription factor binding by physically obscuring the site either 
through recruitment of MBD-containing factors or by the methyl group itself (221). This is highly 
dependent upon the local environment of the TFBS and may vary between transcription factors; in 
fact, methylation of TFBS can increase transcriptional activity of certain transcription factors 
(222). Given this, it is interesting that STAT1 was methylated in both LD and HD (Figure 28), 
since STAT1-dependent genes are upregulated following gp96 treatment. It is interesting to note 
that the STAT1 binding sites observed in LD vs HD are slightly different, and that the HD site may 
also be shared with NFATC2, a transcription factor which becomes activated after TCR 
stimulation. 
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Figure 29. STAT1 is phosphorylated in response to 20 min gp96 stimulation. 
A. Adherent PECs were treated with 200 µg/ml gp96 for 20 min then lysed in NP-40 lysis buffer. IFN𝛄𝛄 and LPS 
treated PECs were included as positive controls. Lysed cells were immunoblotted for pSTAT1-Y701, S727, or 
total STAT1. B-C. Densitometry analysis of PECs. Shown is the fold change in signal compared with PBS 
controls. pSTAT1 levels were normalized to total STAT1 in all experiments. 
5.2.2 gp96 treatment preferentially targets pSTAT1-S727 in CD91+ APCs via a p38 
MAPK-dependent pathway 
To measure STAT1 activity, peritoneal macrophages (adherent PECs) were treated with gp96 for 
20 min. The level of pSTAT1-Y701 and S727 was measured by western blot following treatment. 
IFNγ and LPS treated cells were included as positive controls. IFNγ is known to induce both 
x 
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pSTAT1-Y701 
Total STAT1 
PBS            gp96   LPS 
A. 
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pSTAT1-Y701 and S727, and indeed PECs showed increased signal for both motifs (Figure 
29A,B,C). Gp96 stimulation had little effect on phosphorylation of Y701 at this time point (Figure 
29A,B). However, densitometry analysis showed that the pSTAT1-S727 level in gp96-treated cells 
was ~3 fold higher than PBS treated cells as early as 20 min post treatment (Figure 29A,C). This 
increase was significant. In all samples, pSTAT1 signal was normalized to total STAT1. Total 
STAT1 levels did not change regardless of treatment. Treatment of PECs generated from 
CD91f/fCD11ccre mice with gp96 did not result in increased pSTAT1-S727 (Figure 30A,B), 
demonstrating the need for CD91. These cells were functional since STAT1 was phosphorylated 
upon treatment with LPS (Figure 30A,B). This shows not only that STAT1 phosphorylation in 
response to gp96 is CD91-dependent, but also rules out any contribution from potential LPS 
contamination in our gp96 preparations.  
Given that STAT1 is an important mediator of IFN and other cytokine responses, it is 
possible that the STAT1 activation we have observed is simply an artifact of cytokines present in 
culture, including IL-6 and IL-1β. To rule this out, WT PECs were treated with gp96 for 2 hr. 
Supernatants were then harvested from these cells and transferred onto CD91-deficient PECs. 
CD91-deficient PECs were cultured in these supernatants for 20 min then harvested for western 
blot analysis. If PECs make any factors that work in an autocrine pathway to enhance STAT1 
activation, pSTAT1 should be detected in CD91-deficient PECs. However, pSTAT1 was not 
detectable (Figure 30C,D,E), therefore pSTAT1-S727 is directly due to gp96 stimulation and not 
due to cytokines or other stimuli that may be present in the culture. 
In addition to RAW264.7 cells, PECs also phosphorylate p38 MAPK in response to gp96 
after 20 min stimulation (Figure 31A). To test whether STAT1 phosphorylation was p38-
dependent, PECs were pre-treated for 2 hrs with 10 µM p38-specific inhibitor (SB203580), then 
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cultured with gp96 for 20 min. In the presence of this inhibitor, pSTAT1-S727 was no longer 
observed (Figure 31B). Taken together, these results suggest that the S727 residue is preferentially 
targeted downstream of CD91-gp96 interaction via a p38 MAPK-dependent pathway.  
 
Figure 30. STAT1 phosphorylation is CD91 dependent and is not due to soluble factors produced by PECs. 
A. Adherent CD91-deficient PECs were treated with 200 µg/ml gp96 for 20 min then lysed in NP-40 lysis 
buffer. LPS treated PECs were included as positive controls. Lysed cells were immunoblotted for pSTAT1-
S727 or total STAT1. B. Densitometry analysis of PECs. Shown is the fold change in signal compared with 
PBS controls. pSTAT1 levels were normalized to total STAT1 in all experiments. C. Wildtype PECs were 
treated with 200 µg/ml gp96 for 2 hr. Supernatants were then transferred to CD91-deficient PECs. The cells 
were cultured in these supernatants for 20 min then immunoblotted for the indicated proteins. D. Densitometry 
of PECs. 
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Figure 31. STAT1 phosphorylation is p38 MAPK-dependent. 
A. PECs were treated with 200 µg/ml gp96 for 20 min, lysed, and immunoblotted for p38 MAPK. 
B. PECs were treated with 10 µM SB203580 for 2 hr prior to gp96 treatment. Cells were then 
treated with 200 µg/ml gp96 for 20 min, lysed, and immunoblotted for STAT1. 
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5.2.3 Gp96-stimulated APCs increase transcription and secretion of CXCL10 and 
promote STAT1 binding to the Cxcl10 promoter 
To confirm our previous findings that gp96-stimulated macrophages express CXCL10, peritoneal 
macrophages were isolated and treated with gp96 for 8 hrs. Cells and supernatants were harvested 
for qPCR and luminex, respectively. A dose-dependent increase in CXCL10 transcript was 
observed at this time point (Figure 32A). In agreement with this, secretion of CXCL10 was also 
increased in response to gp96 (Figure 32B)(30).  
   
Figure 32. gp96 upregulates CXCL10 expression. 
A-B. PECs were isolated from naïve mice and adherent cells were stimulated with 
indicated concentration of gp96 for 8 hr. Cell lysates and supernatants were harvested 
for qPCR (A) and luminex (B). Panel B in this Figure is from Sedlacek et al. (30), 
copyright (2016) Nature Publishing. 
We next sought to understand how gp96 can regulate CXCL10 expression. STAT1 is 
known to bind the Cxcl10 promoter to increase its expression. We identified a putative STAT1 
binding site ~300 bp upstream of Cxcl10 using the binding motif ATTTCCAG identified in Figure 
28 by MEME-ChIP analysis (Figure 33A). PECs isolated from naïve or 5-azaC treated mice were 
pulsed with gp96 for 1 hr. DNA bound by STAT1 was isolated by ChIP. DNA was then amplified 
by conventional PCR and RT qPCR using primers against the putative binding site within the 
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Cxcl10 promoter (Figure 33B,C). STAT1 was enriched ~4-fold at this site following gp96 
treatment compared with untreated cells (Figure 33C). PECs isolated from mice given 5-azaC 
exhibited less STAT1 binding regardless of gp96 treatment.  
 
Figure 33. gp96 triggers STAT1 binding to the Cxcl10 promoter. 
A. Putative STAT1 binding site in Cxcl10 promoter. Arrows indicate primer binding sites. B-C. PECs were harvested 
from naïve mice or mice treated with 5-aza for 48 hrs. Adherent cells were treated with gp96 for 1 hr then harvested 
and lysed. STAT1-bound DNA was isolated by ChIP. Isolated DNA was amplified by conventional PCR and run on 
an EtBr gel. (B) Isolated DNA was amplified by RT qPCR (C). % input was calculated (see Methods). Both methods 
were performed using the same primers.  
5.2.4 NK cells require APCs and intact CXCR3 for maximal IFNγ production in response 
to gp96 
CXCL10 is a known activator of NK cells and can promote their “helper” phenotype. Work from 
our lab has demonstrated that gp96 can enhance this NK cell helper role and is required for 
maximal activation of T cells (30). NK cells do not express CD91 and, when pulsed with gp96 in 
vitro, do not secrete IFNγ (Figure 34A)(30). Thus, NK cells are not directly activated by gp96. 
When these cells are co-cultured with gp96-activated PECs, however, IFNγ secretion increases 
significantly (Figure 34B). To determine whether CXCL10 plays a role in APC-NK cell cross-talk, 
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blocking antibodies to the CXCL10 receptor CXCR3 were added to wells in addition to NK cells. 
As shown in Figure 34C, gp96-dependent IFNγ secretion was diminished in the presence of 
CXCR3 antibody. This work demonstrates that a cross-talk mechanism exists between these two 
cell types to direct gp96-mediated immunity. 
 
Figure 34. APC-NK cell cross-talk occurs in response to gp96 and is CXCR3-dependent. 
All data in this figure generated by ALS. Panels A and B are from Sedlacek et al (30), copyright (2016) Nature 
Publishing. NK cells were isolated by negative selection and incubated with 200 µg/ml gp96 (A) alone or (B) with 
adherent PECs for the indicated times. IFN𝛄𝛄 was detected in the supernatants by ELISA to measure NK cell activation. 
C. NK cells were incubated with 200 µg/ml gp96 with adherent PECs in the presence or absence of CXCR3 
neutralizing antibody. IFN𝛄𝛄 was measured by ELISA.   
5.3 DISCUSSION 
We have demonstrated for the first time a functional link between p38 MAPK activation by gp96 
and anti-tumor immunity. In response to gp96, STAT1 is preferentially phosphorylated on S727 
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via a p38 MAPK pathway, distinct from IFNγ signaling. This activation is sufficient to initiate 
binding to the Cxcl10 promoter and enhance expression. Our preliminary data suggests that 
CXCL10 is critical for APC-NK cell cross-talk and may play a role in promoting the NK cell 
helper role that is established by gp96 immunization. 
5.3.1 Methylation of transcription factor binding sites 
Classically, DNA methylation has been classified as a repressor mark. More recent data has 
suggested its role may be more complex than previously assumed. Using a systematic approach to 
look globally at transcription factor binding, Hu et al. performed protein microarrays to assess 
binding of 1300 transcription factors to methylated sequences. A group of transcription factors 
were unaffected by methylation of their binding sites. Methylation of the Kruppel-like factor-4 
(KLF4) TFBS did not change KLF4 binding affinity, but did result in enhanced transcription of 
KLF4 target genes (222). It is possible that recruitment of co-factors and methyl-binding proteins 
alters the local environment and impacts gene expression. 
We have observed that treatment of mice with 5-azaC results in an inability of macrophages 
to initiate binding of STAT1 to the Cxcl10 promoter. However, our preliminary results also indicate 
that STAT1 activation is compromised in these cells (Figure 35). Reduced pSTAT1-Y701 was 
observed in PECs generated from 5-azaC treated mice (Figure 34A,B). Interestingly, whereas the 
α-isoform of pSTAT1-S727 is targeted in PECs from naïve mice, the β-isoform is phosphorylated 
in 5-azaC PECs. It is clear that 5-azaC treatment alters STAT1 signaling activity.  How this may 
affect STAT1 binding to Cxcl10 is unknown at this time, but we cannot rule out this as a possibility. 
5-azaC treatment can have off-target effects such as cholesterol metabolism interference and 
aberrant enzyme activity (223, 224). There are several other DNMT inhibitors that are available 
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and potentially less detrimental to normal cell function, including zebularine and SGI-1027; 
however, these inhibitors may not be as effective as 5-azaC (225). In the future, we aim to use 
DNMT-deficient cells to specifically interrogate the effects of methylation on STAT1 binding.  
 
Figure 35. 5-aza treatment alters STAT1 activity. 
A-B. Mice were treated with 5 mg/kg 5-aza and PECs were isolated 48 hr later. Adherent cells were treated with 200 
µg/ml gp96 for 20 min. Cell lysates were immunoblotted for STAT1 phosphorylation in PECs from naïve mice (A) 
or 5-aza treated mice (B).  
5.3.2 Activation of STAT1 and its specific gene signatures 
Consistent with what has been shown in other systems (97), we have observed p38-dependent 
phosphorylation of STAT1 in response to gp96.  Others have used in vitro assays to test whether 
active ERK1, JNK1, p38 MAPK, MEK1, and MSK1 can result in STAT1 phosphorylation (226). 
JNK and p38 were both identified as indirect activators of STAT, although its direct activator was 
not identified. 
The mechanisms governing STAT1 activation have largely been studied in the context of 
IFN responses. It has become clear that IFN-independent STAT1 activation may act differently in 
terms of how STAT1 is phosphorylated and which genes are targeted. S727 phosphorylation in 
response to microbial products, viral challenge, and IL-1β treatment is sufficient for STAT1 
nuclear translocation and target gene expression (93, 97, 227). The rapidity with which we observe 
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pSTAT1-S727 following gp96 treatment and its dependence on CD91 suggests that gp96 directly 
enhances STAT1 phosphorylation. It is possible that Y701 is phosphorylated at a later time point, 
either due to gp96 itself or indirectly through production of other cytokines (including IL-1β and 
IL-6) known to activate pSTAT1-Y701. If this is indeed the case, then CD91 may utilize a STAT1 
activation mechanism similar to TLRs (97). Regardless of the pathway being utilized, it is clear 
that stimulation with gp96 results in STAT1 binding to the Cxcl10 promoter in macrophages. 
Further experimentation is required to understand the dynamics of pSTAT1 at both the S727 and 
Y701 sites. 
The role of pSTAT-S727 in the absence of Y701 phosphorylation has been reported using 
several systems. Varinou et al. designed gene-targeted mutant mice which express an 
unphosphorylatable STAT1 S727 site (serine to alanine mutation)(228). These mice were less 
likely to succumb to septic shock induced by LPS treatment. While STAT1 binding to target genes 
was unaffected in these mice, recruitment of cofactors including histone acetyltransferases was 
diminished. Studies using macrophages have shown that stimulation of various TLRs results in 
rapid induction of pSTAT1-S727, and that pSTAT1-Y701 does not appear until later time points 
(60-180 min post-treatment). However, pSTAT1-S727 was sufficient for STAT1 translocation to 
the nucleus. Similarly, stimulation of pancreatic β cells with IL-1β results in pSTAT1-S727 and 
binding of STAT1 to the promoters of Cxcl1 and Cxcl2 (227). It has been established that activation 
of STAT1 through this non-canonical pathway does not involve IFN. Finally, pSTAT1-S727 alone 
is required for expression of Fas/Fas ligand and certain caspases, suggesting that phosphorylation 
of S727 is sufficient for transcriptional activity of STAT1 (229, 230). It is also possible that 
pSTAT1-S727 can dimerize with other transcription factors in response to gp96, including STAT3 
and IRF1.   
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In our system, it appears that PECs exhibit a low level of pSTAT1-S727 under basal 
conditions. Basal activity of STAT1 has been observed in a monocyte-like human cell line (231), 
RAW 264.7 macrophages (232), and mouse bone marrow-derived macrophages (233). Gp96 
treatment elevates these levels similarly to LPS and IFNγ, albeit to a slightly lesser extent. The 
baseline STAT1 activity may contribute to the low levels of CXCL10 produced by untreated PECs 
in our study (Figure 29A, 32B). Because the Cxcl10 promoter also contains an NF-κB binding site, 
it is possible that there exists some cooperativity between transcription factors that are activated 
downstream of CD91. We are currently investigating how CXCL10 transcription can be altered by 
treatment of p38 inhibitor (SB203580), NF-κB inhibitor (cardamonin), or a combination of the 
two. Our preliminary data also suggests that CXCL10 production by different APC types is not 
equal in response to gp96. More work is required to determine if this is due to a deficit in STAT1 
signaling in different cell types. To this end, we are developing assays to further interrogate CD91 
signaling on a molecular level using RAW264.7 macrophages that lack one or both of the NPXY 
signaling motifs on CD91. We are also investigating whether different cell types express increased 
basal levels of DUSP1, a phosphatase capable of targeting p38 MAPK.  
5.3.3 APC-NK cell cross-talk and the role of NK cells in cancer 
Although NK cells do not require antigen presentation by APCs to become activated, 
communication between these cells does exist, and under certain circumstances one cell type can 
enhance the activation of the other. Often this feedback primes NK cell helper phenotype; whereas 
NK cells are well known for their ability to kill tumor cells directly, various stimuli can result in a 
helper phenotype in which the NK cells produce factors to enhance maturation of APCs and 
tumoricidal activity of T cells. We have observed that NK cells co-cultured with APCs in vitro can 
 100 
enhance APC maturation in response to gp96 (ALS, unpublished data). Treatment of NK cells with 
IL-18 can promote secretion of proinflammatory cytokines and chemokines which attract DCs and 
T cells to the tumor microenvironment (234). Fernandez et al. used a mouse tumor cell line (AK7) 
that expresses low to no MHC I and II, making it a strong target of NK cell lysis (235). Prior to 
AK7 tumor challenge, mice were treated with Flt3 ligand to expand DCs in vivo. Expansion of the 
DC population enhanced tumor killing compared with mice that were not given Flt3 ligand, 
demonstrating DC-NK cell cross-talk exists within a tumor setting. Co-culture studies with NK 
cells and DCs have shown that interaction between these cell types does occur and results in release 
of pro-inflammatory mediators IL-6, TNF, IL-8, GMCSF, and IFNγ (236). Cell-cell contact is 
regulated through release of activin A, creating a negative feedback loop and terminating cytokine 
release. It is possible that, in our system, NK cell production of IFNγ may create a STAT1 feedback 
loop on the APCs, further driving CXCL10 secretion. We are currently testing whether this occurs. 
Previous studies from our lab have shown that gp96-stimulated APCs enhance IFNγ 
production (28).  We have expanded upon this and show here that CXCR3 is required for full 
activation of NK cells co-cultured with gp96-stimulated APCs. In addition to CXCL10, CXCR3 
also binds CXCL9 and CXCL11. We have not ruled out the possibility that these other chemokines 
may be playing a role in activating NK cells in our model. We plan to follow up on these 
experiments using NK cells that are deficient in CXCR3 expression (CXCR3f/fNK1.1cre) and APCs 
that are deficient in CXCL10 expression (CXCL10f/fCD11ccre) to confirm our findings. 
Nevertheless, both CXCL9 and CXCL11 are STAT1 target genes, which still supports our 
hypothesis. 
When present at elevated doses, CXCL10 activates naïve NK cells to become lytic and 
improve T cell proliferation (237). In this study, mice were challenged with either wildtype DA1-
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3b tumor cells or DA1-3b that was engineered to overexpress CXCL10. Isolated CD8+ T cells and 
NK cells both exhibited greater lytic potential using an in vitro killing assay. The ability of T cells 
to lyse DA1-3b was significantly amplified when co-cultured with NK cells, suggesting that the 
CXCL10-conditioned NK cells facilitated T cell activation. Additionally, using labeled NK cells 
and tumor cells visualized by in vivo fluorescence imaging, Wennerberg et al. observed increased 
NK cell infiltration into tumors that express CXCL10 compared with tumors that did not express 
CXCL10 (238).  It is possible that, in addition to skewing NK cell activation, CXCL10 production 
by gp96-stimulated APCs in the tumor microenvironment can lead to recruitment of NK cells.  
It was shown several decades ago that prevention of tumor metastasis following gp96 
immunization requires NK cells (32). Few studies have measured NK cell activity in humans 
treated with tumor-derived gp96, and the data that has been published has largely been correlative. 
One study found a higher frequency of NK cells in peripheral blood of patients treated with gp96 
(34). Subsequent studies in mice suggest that co-administration of gp96 and IL-2 can significantly 
augment the NK cell population and prime them to become more protective in response to 
pathogen challenge (239). What has not been shown, however, is whether gp96 immunization can 
result in homing of NK cells to target tissues including tumor.  
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6.0  THESIS SUMMARY AND FUTURE DIRECTIONS 
6.1 SUMMARY 
Although HSPs are normally found within the cytosol and endoplasmic reticulum of their host 
cells, they may be released through cell death, expressed on the surface in response to cell stress, 
or introduced locally through vaccination. When this occurs, gp96 and other immunogenic HSPs 
may bind to APCs via their receptor CD91 to elicit specific immunity against the HSP-bound 
peptide. This phenomenon is precisely dose-dependent in that LD immunization results in Th1 and 
CTL-mediated responses, whereas higher doses are associated with Treg induction and immune 
suppression. The number of cells that are compromised and release HSP becomes important; small 
tumors prime anti-tumor immune responses whereas large tumors elicit immune 
hyporesponsiveness. 
My data from Chapter 1 demonstrates that CD91-expressing APCs are required to elicit 
HD immunity. CD91 was found to be highly expressed by two major DC subsets: the 
CD11b+CD11c+ cDCs and CD11clowB220+PDCA+ pDCs. Both subsets internalize gp96 at LD and 
HD; however, it seems that cDCs are saturated at HD and do not constitute a higher percentage of 
gp96+ cells as dose is increased. Yet following HD gp96 administration, there is a 5-fold increase 
in the percent of gp96+ pDCs in the draining lymph node, suggesting these cells are actively 
targeted at higher doses.  
Chapter 2 establishes that DNMTs form punctae in the nuclei of various gp96-stimulated 
APCs. This change in DNMT architecture was correlated with genome-wide methylome 
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remodeling in CD91+ cells isolated from LD and HD gp96 immunized mice. The most robust 
differences in methylation were detected within gene families associated with cell-cell 
interaction/adhesion. Specifically, HD gp96 could induce increased expression and gene-body 
methylation of Nrp1 in pDCs. Gp96-stimulated pDCs co-cultured with Treg established stable, 
Nrp1-dependent interactions. Intact pDCs and Nrp1 was required to elicit HD immunity. Taken 
together, it is clear that gp96 may trigger unique genetic and epigenetic events depending on the 
type of APC. When gp96 favorably engages cDCs, such as during LD immunization, co-
stimulatory molecule and cytokine secretion dictates the CTL response; following HD 
immunization, pDCs are preferentially bound and drive Treg responses via Nrp1. 
 Finally, Chapter 3 focuses on a newer area of research to establish a mechanism to explain 
the previously published phenomenon of APC-NK cell crosstalk in response to gp96. P38 MAPK 
is phosphorylated in gp96-treated PECs and this in turn activates pSTAT1-S727. STAT1 binds to 
a promoter sites upstream of Cxcl10, driving its expression. CXCL10 requires its receptor, 
CXCR3, to trigger NK cells. When CXCR3 is neutralized, APC-NK cell crosstalk is abolished and 
IFNγ production by NK cells is impaired. Future experimentation is required to fully understand 
this novel STAT1 pathway downstream of CD91. For example, time course experiments need to 
be performed in order to understand the dynamics of pSTAT1-S727 and whether pSTAT1-Y701 
can be detected at later time points. We are also interested in how STAT1 activation can influence 
NK cell activation. Future experimentation will be performed using STAT1-deficient APCs co-
cultured with NK cells.  
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6.2 FUTURE DIRECTIONS 
6.2.1 Lymph node architecture and how gp96 engages pDCs versus cDCs 
pDCs in the draining lymph node take up more gp96 at HD and drive the suppressive Treg 
response. What we have not shown is how this is possible. pDCs normally reside within the T cell 
zone of secondary lymphoid tissues including lymph nodes. Yet we have previously observed that 
gp96 is localized to the subcapsular sinus following immunization in the skin (61). We propose 
that, at HD, gp96 may either infiltrate deeper into the lymph node to reach pDCs, or pDCs migrate 
to the subcapsular sinus in response to factors produced by gp96+ macrophages and DCs. In 
response to viral infection, lymph node resident sinusoidal macrophages produce IFNs which 
drives relocalization of pDCs from the deep cortex to the subcapsular sinus and medulla (240). In 
the future, experiments will be performed using gp96A488 to visualize by microscopy whether 
higher doses can diffuse deeper within lymph nodes. pDC localization in response to immunization 
will also be observed. 
6.2.2 Implications for clinical trials: Dosage and microneedle arrays 
Given the data I have presented here, preventing gp96 uptake by pDCs in the context of cancer 
immunotherapy may improve the results of current clinical trials. Tip-loaded dissolvable 
microneedle arrays (TL-dMNAs) are a promising new technology that provide local delivery of 
therapeutics into the skin (241). The microneedles on TL-dMNAs can be loaded with precise 
amounts of therapeutic. When injected into skin, the microneedles are embedded and quickly 
dissolved within the dermis, allowing for local uptake of their contents. In collaboration with Louis 
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Falo, we will test whether gp96 injected with TL-dMNAs results in uptake by skin DC and 
preclusion of drainage into lymph nodes. We are currently testing if pDCs can take up TL-dMNA 
administered gp96 and whether this is a viable anti-cancer therapeutic in vivo. Our preliminary 
flow cytometry data suggests that HD gp96A488 is not taken up by pDCs if injected using these 
methods. If enhanced tumor protection is observed, TL-dMNAs may provide an exciting new route 
for clinical trials by circumventing uptake by suppressive DCs.   
Additionally, we propose that HD gp96 can be used as a clinical therapy in autoimmunity 
and solid organ transplantation. To date, HD gp96 efficacy has not been measured in humans 
outside of in vitro studies. Increased soluble and cell-surface gp96 has been detected in the 
inflamed joints of RA patients (115-117). This is a macrophage-rich microenvironment, and 
uptake by these macrophages enhances inflammation (117). pDCs are also involved in the 
pathology of RA and other autoimmune diseases by producing large amounts of type I IFNs and 
exacerbating disease (242, 243). I have presented data in this thesis to suggest that gp96 can 
promote a suppressive phenotype in pDCs. We have not yet tested whether gp96 treatment is 
sufficient to switch the phenotype of IFN-producing pDCs in autoimmune patients. More 
experimentation is needed to understand the effect of gp96 on pDCs, and how gp96 uptake can be 
enhanced to treat autoimmune diseases such as RA. 
6.2.3 CD91 in cholesterol storage and metabolism 
Many questions remain open regarding CD91 signaling in the immune system. As it is part of the 
LDL receptor family, CD91 is closely tied to cell metabolism. Uptake, processing, and 
accumulation of cholesterol is controlled by CD91 in multiple cell types including vascular smooth 
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muscle cells and macrophages (76, 244). Canonical Wnt5a and p-GSK3β pathways are activated 
downstream of CD91 and play a pivotal role in cholesterol storage (77). In this study, impairment 
of CD91 led to enhanced cholesterol storage and fatty acid synthesis via Wnt and GSK3β, 
respectively. We have found that pDCs isolated from CD91f/fCD11ccre mice exhibit a defect in 
baseline p-GSK3β levels compared with wildtype (Figure 36). It may be that metabolism in these 
cells is dysfunctional, although this remains to be formally tested. 
 
Figure 36. CD91-deficient pDCs have less p-GSK3β at baseline compared with wildtype. 
pDCs were treated with 200 ug/ml gp96. After 15 min, cell lysates were harvested for western 
blot analysis and probed with the indicated antibodies. 
  
We have interrogated CD91 expression on multiple APC types, with the data presented in 
this thesis and elsewhere. Expression and function of CD91 on non-APC immune cells such as T 
cells has not been extensively reported. Research into the metabolism of naïve, effector, and 
memory T cells has exploded in recent years. It is now apparent that naïve and memory T cells 
rely on fatty acid metabolism, whereas activated effector T cells require glycolysis to support the 
massive expansion during the effector phase of the immune response (245). CD4+ T cells can be 
differentially identified by flow cytometry using the following markers: CD44-CD62L+/-CD25- 
(naïve), CD44+CD62L-CD25+ (effector), CD44+CD62L-CD25- (effector memory), and 
CD44+CD62L+CD25- (central memory). Interestingly, our preliminary data shows transient, high 
CD91 expression exclusively on CD44+CD62L+CD25-  central memory T cells from mice 
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immunized with irradiated SVB6 tumor cells (Figure 37).  Effector and effector memory T cells 
showed some intermediate expression compared with secondary only controls. Whether CD91 
expression plays any role in fatty acid metabolism in these cells is an area of active interest in our 
lab.  
 
Figure 37. Central memory CD4+ T cells express CD91 following immunization. 
Mice were immunized i.d. with irradiated SVB6 tumor cells. Draining lymph nodes were harvested 1 or 4 wk later 
and analyzed by flow cytometry. Cells were gated using the indicated markers and plotted for CD91 expression. 
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7.0  MATERIALS AND METHODS 
7.1.1 WT mice  
Female C57BL/6 mice were obtained from Jackson Laboratories (Bar Harbor, ME) and housed in 
DLAR at the University of Pittsburgh. All mice were 6-8 weeks old and all experimental 
procedures were approved by the Institutional Animal Care and Use Committee and performed in 
compliance with its guidelines.  
7.1.2 Generation of CD91f/fCD11ccre mice 
CD91fl/+ mice were purchased from Jackson Laboratory (Bar Harbor, ME) and mated to 
homozygosity (CD91fl/fl). CD91fl/fl mice were crossed with CD11ccre to generate mice that were 
selectively deficient of CD91 on CD11c-expressing cells. These mice were previously 
characterized and have normal numbers of APCs and lymphocytes (26).  
7.1.3 Cell lines 
D122 and B16.F10 cells were cultured in DMEM containing 1% sodium pyruvate, 1% L-
glutamine, 1% nonessential amino acids, 1% penicillin and streptomycin, 0.1% 2-
mercaptoethanol, and 10% fetal bovine serum (FBS) (GIBCO). B16-OVA cells were cultured in 
complete DMEM supplemented with 5 mg/ml G418. Adherent cells were harvested using trypsin. 
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The mAb927 hybridoma was cultured in complete RPMI containing 10% FBS (GIBCO). 
Cells were serum starved for 3 days, supernatants were harvested, dialyzed, and run through a 
Melon Gel column (Thermo Fisher) for purification of the α-PDCA antibody. Antibody 
preparations were analyzed by SDS-PAGE.    
7.1.4 Isolation of primary spleen cDCs, pDCs, NK cells, and T cells 
All ex vivo isolated cells were cultured in RPMI containing 1% sodium pyruvate, 1% L-glutamine, 
1% nonessential amino acids, 1% penicillin and streptomycin, 0.1% 2-mercaptoethanol, and 5% 
FBS (GIBCO). pDCs were isolated from mouse spleens using anti-PDCA1 microbeads according 
to the manufacturer’s protocol (Miltenyi Biotec) and cultured in complete RPMI. For all pDC 
stimulation assays ex vivo, 5x105 cells were plated in round bottom plates with 10 µg/ml or 200 
µg/ml gp96, or equivalent volume of PBS. For 5-azaC treated pDC generation, mice were 
administered 5 mg/kg 5-azaC in a total volume of 200 µl i.p., and pDCs were isolated by magnetic 
magnetic-activated cell sorting (MACS) after 72 hr. NK cells were isolated using MACS kits with 
untouched protocols by negative selection using the NK cell isolation kit II. Isolation of Treg and 
Tconv were performed using the CD4+CD25+ regulatory T cell isolation kit. All non-T cells are 
first depleted from bulk splenocytes. T cells were separated from Treg using CD25 selection; the 
CD25+ population was used for Treg, the CD25- population was used for Tconv. Isolations 
typically yielded at least 80% purity for all kits.  
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7.1.5 Generation of primary murine BMDCs and PECs 
BMDCs; bone marrow cells were isolated from the femurs of female C57BL/6 and cultured in 
complete RPMI (10% FBS). Cells were cultured in RPMI supplemented with GM-CSF (Fisher 
Scientific). Media was supplemented after 3 days of culture and loosely adherent cells were 
harvested 6-7 days following initial plating. These cells were used as representative cDC 
populations for indicated in vitro experiments. BMDCs were plated at 5x105 cells/well with 200 
µg/ml gp96. PECs were isolated by peritoneal lavage of naïve or 5-azaC-treated mice with sterile 
PBS. Cells were plated for at least 6 hr, and non-adherent cells were removed.  
7.1.6 Purification of HSPs 
Purification of HSPs. In all experiments, gp96 was purified from mouse livers. Mouse livers were 
harvested and homogenized with a blender to a single cell suspension. Protein was stepwise 
precipitated out of an ultracentrifugation (100,000g) supernatant to 80% saturation stepwise. 
Protein was passed over immobilized Concanavalin A columns. Bound fraction was eluted with 
10% mannose and buffer-exchanged with PD10 columns into 0.005M sodium phosphate solution 
containing 0.3M NaCl. This was applied to equilibrated DEAE columns. Bound fraction was 
eluted with 0.7M NaCl. Fraction 3-5 contained gp96 as assessed by SDS-PAGE and 
immunoblotting. We fully characterized all gp96 preparations; purity of gp96 preparations was 
assessed by SDS-PAGE gp96 and was determined to be a homogenous 96kDa protein (Figure 4A). 
The protein was recognized by a monoclonal gp96 antibody (clone 9G10, Enzo Life 
Sciences)(Figure 4B). Further, gp96 retained its enzymatic ATPase activity (Figure 4C). ATP 
hydrolysis was measured using the ATPase/GTPase Activity Assay kit (Sigma). Gp96 (10 
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mg/well) was incubated for indicated period of time with ATP at 37°C in a 96-well plate. Malachite 
green was added and absorbance was read at 600 nm. ATP hydrolysis was calculated using a 
standard curve. Gp96 was determined to be free from endotoxin contamination by LAL assay and 
western blot. Gp96 concentrations were determined by the Bradford assay. Preparations of gp96 
were labeled with Alexafluor 488 (Invitrogen, Grand Island, NY) as recommended to obtain 
gp96A488. Each molecule of gp96 was calculated to be labeled with four to nine molecules of A488. 
Protein was analyzed with standard SDS-PAGE and immunoblotting with anti-gp96 (Enzo Life 
Sciences Farmingdale, NY) and anti-A488 (Invitrogen, Grand Island, NY). All gp96 
immunizations were delivered i.d. in a final volume of 100 µl PBS (LD = 1 µg; HD = 10 µg). For 
better resolution of gp96 in vivo, all gp96A488 immunizations were delivered s.c. in a final volume 
of 100 µl PBS (LD = 10 µg; HD = 100 µg). For all in vitro assays using cDCs or pDCs, cells were 
cultured with gp96 at the indicated concentration or an equivalent volume of PBS. 
7.1.7 In vivo tumor growth assay 
For active immunization, tumor cells were irradiated (6000 rad) and 1x106 cells were injected s.c. 
as indicated. One week later, mice were injected with PBS, LD gp96 (1 µg), HD gp96 (10 µg), or 
MSA. One week following treatment, mice were subsequently challenged i.d. with 5x104 tumor 
cells and monitored for tumor growth by measurement on two axes. For IL-12 experiments, mice 
were injected i.p. with 0.25 µg recombinant IL-12 on the same day as gp96 treatment and every 
day for 3 days following. Seven days after gp96 injection, mice were challenged with 5x104 tumor 
cells. IL-12 treatment was based on previously published experiments using similar systems (246). 
For all experiments, mice were sacrificed when tumors were 1.5 cm in any one diameter according 
to IACUC approved protocols. Group size was determined by power analyses in each experiment.  
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7.1.8 MBD methyl-sequencing and analysis 
Mice were immunized i.d. with LD or HD gp96 or with PBS and sacrificed after 18 hr. Draining 
lymph nodes were harvested and CD91+ cells were isolated by FACS using a FACSAria 
instrument (BD Biosciences). DNA was purified, sonicated to an average size of 300 bp using a 
Bioruptor (Diagenode), and enriched for methylated sequences using MBD purification using the 
MethylMiner Enrichment Kit (Invitrogen). Precipitated DNA was analyzed for quality assurance 
prior to sequencing. Methylated fragments were sequenced using an Ion TorrentN sequencer (Life 
Technologies) at the Genomics and Proteomics Core (University of Pittsburgh, PA). The samples 
were sequenced to an average of 45 million reads. Raw sequencing reads (fastq format) were 
mapped to the mouse genome (mm9) using Bowtie 2, which can account for large gaps in 
sequencing reads. Only non-redundant and uniquely mapped reads were used for subsequent 
analysis. Methyl peaks were assigned using Model-based Analysis for ChIP-Seq software (247) 
with PBS treated mice used as a reference sample. Peaks were merged based on overlapping and 
book-end peaks, and coverage was calculated using BEDtools merge version 2.17.0. Peaks were 
annotated with the annotation provided by UCSC using a custom Perl wrapper and Tabix (248). 
Peaks within 2000 bp of a coding sequence were reported with annotation. Comparison of peaks 
and identification of DMRs was performed similar to previously reported studies by the University 
of Pittsburgh Bioinformatics Core using GEDA (Genome Expression Data Analyzer) software and 
Efficiency Analysis (249-251). DMRs were visualized using the UCSC Genome Browser and 
Genomatix software. Global distribution of intragenic DMRs (exon, intron, promoter) was 
performed using Genomatix Genome Analyzer (Genomatix Software GmbH). Distribution across 
TSS and CpG islands was determined using SeqMonk (Babraham Bioinformatics). Transcription 
factor binding analysis was performed using Genomatix software. Genetrail (252) was used to test 
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for gene ontology analysis using default parameters and Ensembl genes as background for 
enrichment. Results were corrected for multiple testing using Bonferroni adjustment. 
7.1.9 Bisulfite sequencing 
Mice were immunized as described for MBD methyl-seq experiments and CD91+ cells were 
isolated by FACS. For pDC experiments in vitro, splenic pDCs were isolated and pulsed with 
200µg/ml gp96. Cells were harvested after 6 hr in Puregene cell lysis buffer (Qiagen) prior to DNA 
extraction. Genomic DNA was bisulfite converted with the EZ Lightning DNA Conversion Kit 
according to the manufacturer’s protocol (Zymo Research). Methylated and unmethylated DNA 
controls were spiked into each sample to control for completeness of the bisulfite conversion. 
Bisulfite-converted DNA was amplified by PCR (F primer: 
TTGTATTGAGGTATATAAAGTTGGTA, R primer: 
AATTCAAAAACACAAATTTCTCTCC) and the amplicons were cloned using TOPO TA 
vectors (Invitrogen). Primers were designed using MethPrimer software (253). Colonies were 
isolated and minipreps were performed to isolate DNA. The DNA was then sequenced for Nrp1. 
Both CpG and non-CpG were considered in analyses.  
7.1.10 Chromatin accessibility assay 
Naive pDCs and total CD11c+ DCs were isolated from C57BL/6 spleens using anti-PDCA and 
anti-CD11c MACS isolation kits (Miltenyi Biotec) according to manufacturer protocols. 
Chromatin was immediately purified and digested from isolated DCs using the EpiQuik chromatin 
accessibility assay kit (Epigentek). Chromatin preps from each sample were split in two, and were 
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treated with nuclease (Nse) mix or left untreated. DNA was amplified using quantitative PCR 
using primers specific for the Nrp1 region identified from the methyl-seq/bisulfite seq screen. Fold 
enrichment was calculated using the formula: FE = 2^(NseCT-noNseCT) x 100%. Samples were 
validated using positive and negative control primers provided by manufacturer.  
7.1.11 Microscopy and analysis 
Non-confluent cells (BMDCs, cDCs, pDCs, and PECs) were grown overnight on coverslips at 37o 
C then pulsed with PBS or gp96 for 6 hr. Cells were then washed, fixed in 2% paraformaldehyde 
for 15 min, permeabilized with triton X-100 for 15 min, blocked with 2% bovine serum albumin 
(BSA), and stained in 0.5% BSA with primary antibody anti-DNMT1 (clone 60B122.1, Epigentek) 
at a dilution of 1:100. Secondary antibodies were conjugated to Cy3, Cy5, or AF488. F-actin was 
stained with phalloidin-488 and nuclei were stained using Hoescht stain. All images were captured 
using an Olympus FV1000 confocal microscope. DNMT puncta were quantified using analyses 
developed by the Center for Biologic Imaging (University of Pittsburgh, PA) which calculates 
punctae intensity based on intensity threshold using NIS Elements (Nikon). The number of puncta 
per field of view were normalized to the total number of cells in that field of view. For cardamonin 
studies, PECs were treated with high dose gp96 in the presence of 10 mM cardamonin or 
equivalent amount of DMSO. Cells were stained for DNMT after 6 hr incubation at 37°C. 
7.1.12 Western blotting 
For DNMT western blotting, nuclear extracts were isolated using Epiquik Nuclear Extraction Kit 
(Epigentek). DNMT1 (clone 60B122.1; Epigentek) and Lamin B1(clone L-5; Invitrogen) 
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antibodies were used in immunoblots and were developed using X-ray film. Bands were quantified 
using ProteinSimple technology. For all other western blotting, cells were lysed in NP-40 lysis 
buffer supplemented with protease/phosphatase inhibitor cocktail. GSKα/β (clone D75D3, CST) 
phospho-GSK3β Ser9 (clone 5B3, CST), STAT1 (clone D1K9Y, CST), phospho-STAT1 Ser727 
(clone D3B7, CST), phospho-STAT1 Tyr701 (clone 58D6, CST), p38 (clone D13E1, CST), 
phospho-p38 Thr180/Tyr182 (clone 28B10, CST), and β-actin antibodies were used. 
7.1.13 Live cell imaging and analysis 
Live cell imaging and analysis. Splenic pDCs were plated at 5x105 cells/dish in 35-mm collagen-
coated glass-bottom culture dishes (MatTek) in 10% FBS complete RPMI. Cells were pulsed with 
PBS or low dose or high dose gp96 for 18 hr. CD4+CD25+ Tregs or CD4+CD25- Tconv were 
isolated from spleen using Treg isolation kit (Miltenyi) and labeled with CellTracker Red dye prior 
to addition to the culture and imaging. Nrp1 blocking monoclonal antibody (clone 761704; RnD 
Systems) or rat IgG2a isotype antibody (clone eBR2a; eBioscience) were added 2 hr prior to 
imaging at a final concentration of 10 mg/ml. Antibody clones and concentrations were based on 
previously established protocols (197). Cells were imaged on a Nikon A1 inverted microscope 
(Nikon) using a 40X objective. Images were captured every 5 min for a total of 1 or 2 hr. Videos 
were analyzed using NIS Elements (Nikon) and ImageJ (254) with Manual Tracking plugin. For 
interaction time analysis, total contact duration per Treg/Tconv detected from videos was 
calculated based on the number of frames in which a Treg/Tconv came in contact with a pDC. 
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7.1.14 Flow cytometry 
Flow cytometry. Conjugated antibodies included: APC/Cy7 anti-CD11c (clone HL3, BD), PerCP-
Cy5.5 anti-CD11b (clone M1/70, BD), APC anti-PDCA-1 (clone eBio927, eBioscience), BV421 
anti-Nrp1 (clone 3E12, BioLegend), FITC anti-B220 (clone RA3-6B2, BD), anti-Lrp1 (clone 5A6, 
Abcam), PerCP-Cy5.5 anti-CD4 (clone RM4-5, BD), and APC anti-Foxp3 (clone FJK-16s, 
eBioscience). Surface marker staining was performed in staining buffer (0.5% BSA + 0.1% sodium 
azide in 1X PBS) at a 1:100 dilution for 20 min on ice followed by washing. Foxp3 staining was 
performed using overnight fixation and specific staining kit (eBioscience) after staining for surface 
markers. CD91 staining was performed at 4o C for 30 min following a 15 min fixation with BD 
fix/perm buffer. All experiments were performed using BD LSR II and BD LSRFortessa 
instruments and analyzed using FlowJo software.  
7.1.15 In vivo T cell suppression assay 
On day 1, C57BL/6 mice were immunized with 106 irradiated (6000 rad) B16 or B16-OVA cells 
i.p. in 200 µl PBS. Mice were allowed to rest 4-6 hr then administered anti-PDCA (clone mab927) 
or control rat IgG2 in 200 µl PBS for depletion of pDCs. Each mouse received 400 µg i.p., 
consistent with previous studies using this antibody for in vivo depletion (255). pDC depletion was 
measured by the percent of pDCs present in the blood at the time of gp96 immunization (Figure 
38), which confirmed at least ~90% depletion at this time point. One day later, mice were given 
HD gp96 i.d. On day 7, C57/BL6 mouse splenocytes were divided, pulsed with SIINFEKL peptide, 
and CFSE labeled. Unpulsed (CFSE-low) and SIINFEKL-pulsed (CFSE-high) were mixed at a 
1:1 ratio and 1-2x107 cells were injected intravenously via tail vein. Recipient mice were sacrificed 
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5 hr later and analyzed by flow cytometry for lysis of the fluorescently-labeled target population. 
Percent cytotoxicity was calculated: (1-(input ratio / sample ratio))*100 
   
Figure 38. pDC depletion. 
Mice were treated with 400 µg anti-PDCA or isotype antibody 
i.p. 24 hr later, mice were bled via tail vein and pDC numbers 
were analyzed by flow cytometry. 
7.1.16 In vivo Nrp1 neutralization assay 
On day 1, C57BL/6 mice were immunized with 106 irradiated (6000 rad) B16-OVA cells i.p. in 
200 ml PBS. Seven days later, mice were given high dose gp96 i.d. in 100 ml PBS (or PBS only 
as control). On the same day, mice also received 100 mg Nrp1 blocking antibody (clone 761704, 
RnD Systems) or 100 mg rat IgG2a isotype antibody (clone eBR2a, eBioscience) via the i.p. route. 
Route and dose of Nrp1 antibody is based on previous reports using this antibody38. One week 
later, all mice were sacrificed and draining lymph nodes were harvested for flow cytometry. The 
percent of Foxp3+ T cells was quantified. 
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7.1.17 Chromatin immunoprecipitation 
3x106 PECs were plated on a flat bottom 24 well plate in 1 ml RPMI and incubated 6 hr at 37o C. 
Non-adherent cells were removed by washing the wells with PBS. PECs were stimulated for 1 hr 
with 200 µg/ml gp96, an equimolar concentration of LPS, 10 ng/ml IFNγ, or equivalent volume 
PBS in a total volume of 0.35 ml. After 1 hr, supernatants were removed and 1.5 ml 1% 
formaldehyde solution (in serum-free RPMI) was added to each well to cross-link DNA. The plate 
was rocked at room temperature for 10 min. The formaldehyde solution was removed, 1.5 ml 1X 
glycine stop solution was added, and the plate was rocked at room temperature for 10 min. Cells 
were trypsinized, washed, and cell pellets were resuspended in lysis buffer. Lysates were sonicated 
using Bioruptor pico (Diagenode): 30s on, 30s off for 7 cycles. Lysates were run on a gel to confirm 
that the samples were fully sonicated to 100-300 bp. Using anti-STAT1 or isotype antibodies, 
DNA-protein complexes were precipitated, reverse cross-linked, and treated with proteinase K. 
STAT1, isotype, and input samples were analyzed by qPCR using the following primers designed 
against the CXCL10 promoter: (F primer: CCATGGTTAGAACCTGACTTAG; R primer: 
GCAGTGCCTTGCAGAATA). DNA was amplified with SYBER green using the following 
conditions: Taq activation for 10 min at 95 degrees, followed by 40 cycles of 15 s at 95o C and 1 
min at 56o C. Quantification was performed by normalizing STAT1 precipitated samples to input. 
Percent input was calculated by: % input = 2deltaCTx100. 
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7.1.18 ELISA and Luminex 
IFNγ ELISAs were performed with Mouse IFNγ Femto-HS Ready-Set-Go kit (eBioscience). 
Luminex (eBioscience) was used to detect secreted IP-10 protein. Samples were analyzed using 
a Bioplex II Luminex machine (Bio-Rad). 
7.1.19 Statistical analyses 
Statistical analyses were performed using 2-tailed t test for comparison between 2 variables or 
ANOVA with Tukey multiple corrections tests for comparison between 3 or more variables. For 
tumor growth studies, ANOVA of area under curve (AUC) analysis was used. Statistical 
significance was defined as P<0.05. Graphs are presented as mean ± standard error of mean (SEM) 
or standard deviation (SD) as noted. Statistical analyses were performed using Prism software 
(GraphPad, La Jolla, CA). ns, not significant; * P<0.05, ** P<0.01, *** P<0.001 
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